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ABSTRACT
The binding of HI V- I Vifto the cellular cytidine deaminase Apobec3G and
subsequent prevention of Apobec3G virion incorporation have recently been identified as
critical steps for the successful completion of the HIV - 1 viral life cycle. This interaction
occurs in the cytoplasm where Vif complexes with Apobec3G and directs its degradation
via the proteasome pathway or sequesters it away from the assembling virion, thereby
preventing viral packaging of Apobec3G.
While many recent studies have focused on several aspects of Vif interaction with
Apobec3G, the subcellular localization of Vif and Apobec3G during the viral life cycle
have not been fully considered. Inhibition of Apobec3G requires direct interaction ofVif
with Apobec3G, which can only be achieved when both proteins are present in the same
subcellular compartment.
In this thesis, a unique approach was utilized to study the impact of Vif
sUDcellular localization on Vif function. The question of whether localization could
influence function was brought about during the course of studying a severely attenuated
viral isolate from a long-term non-progressor who displayed a remarkable disease course.
Initial observations indicated that this highly attenuated virus contained a mutant Vif
protein that inhibited growth and replication. Upon further investigation , it was found
that the Vif defect was atypical in that the mutant was fully functional in in vitro assays
Vll
but that it was aberrantly localized to the nucleus in the cell. This provided the basis for
the study of Vif localization and its contribution to Vif function.
In addition to the unique Vif mutant that was employed , while determining the
localization and replication phenotypes of the differentially localized Vif proteins, a
novel pathway for Viffunction was defined. Copious publications have recently defined
the mechanism for Vif inhbition of Apobec3G. Vif is able to recruit Apobec3G into a
complex that is targeted for degradation by the proteasome. However, this directed
degradation model did not fully explain the complete neutralization of Apobec3G
observed in cell culture. Other recent works have proposed the existence of a second
complementary pathway for Vif function. This pathway is defined here as formation of
an aggresome that prevents Apobec3G packaging by binding and sequestering Apobec3G
in a perinuclear aggregate. This second mechanism is believed to work in parallel with
the already defined directed degradation pathway to promote complete exclusion of
Apobec3G from the virion.
The data presented here provide insight into two areas of HIV research. First, the
work on the naturally occurring Vif mutant isolated from a long-term non-progress or
confirms the importance ofVif in in vivo pathogenesis and points to Vif as a potentially
useful gene for manipulation in vaccine or therapy design due to its critical contributions
to in vivo virus replication. Additionally, the work done to address the subcellular
localization of Vif led to the proposal of a second pathway for Vif function. This could
have implications in the field of basic Vif research in terms of completely understanding
and defining the functions ofVif. Again, a more complete knowledge about Vif can help
in the development of novel therapies aimed at disrupting V if function and abrogating
HIV - 1 replication.
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CHAPTER I
INTRODUCTION
A. Retroviridae
Retroviruses belong to the family Retroviridae. 
These viruses are defined by their
virion encapsidated, genomic, positive strand RNA that is reverse transcribed by the
enzyme Reverse Transcriptase into double-stranded DNA (dsDNA) upon entry into the
host cell. This reverse transcribed dsDNA is transported to the nucleus where it becomes
integrated into the host genome via the virally encoded Integrase enzyme. The integrated
form of viral DNA is known as the provirus. This provirus drives production of viral
RNA and viral proteins. The integrated provirus allows for production of new viral
particles, persistence of the virus in the host cell , and vertical transmission to progeny
cells.
Retroviral virion particles are spherical and consist of an outer lipid membrane
bilayer studded with Envelope glycoproteins. These Envelope glycoproteins determine
host cell tropism. Beneath this membrane layer , there is a spherical shell composed of
the Matrix protein. The viral core is made up of Capsid encompassing the genomic
RNA, which is coated with Nucleocapsid. Also contained in the viral core are the
Reverse Transcriptase, Protease , and Integrase enzymes.
Retroviruses can be divided into two main classifications based on their genome
composition. The retroviral genome consists of a dimer of single stranded , positive sense
RNA. All Retroviruses contain a 5' cap and 3' poly- A tail similar to mRNA , a R region
at the 5' and 3' ends , 5' and 3' unique regions containing the aft integration sites, a
primer binding site for minus-strand DNA synthesis, a polypurine tract for plus-strand
DNA initiation, a Psi element that governs viral genome packaging, and the gag, pol, and
env genes that code for the structural proteins , viral enzymes, and envelope
glycoproteins , respectively. Viruses that contain only these basic elements , such as
alpha- , beta- , or gammaretroviruses, are known as simple retroviruses. Those that encode
additional auxiliary genes are complex retroviruses. Members of the genus
epsilonretrovirus , spumavirus , or lentivirus are complex retroviruses.
B. Human Immunodeficiency Virus type 1 Infection
1. Background
The genus Lentivirus belongs to the Retrovirus family. Lentiviral characteristics
include extended latent periods and eventual development of diseases associated with the
immune , nervous , or hematopoietic systems (1). The Human Immunodeficiency Virus
type 1 (HIV- 1) is a lentivirus that infects the immune system of humans. A complex
retrovirus, the genome of HIV- l is 9.2kb and encodes the gag, pol, and env genes as well
as the six accessory genes, vif, vpr, vpu , tat , rev , and nef. HIV - 1 targets the CD4 + T
lymphocytes and macrophage cells of the immune system.
HIV - 1 was initially isolated and identified as a retrovirus in 1983 (2). The
following year, three independent groups reported the discovery of a cytopathic retrovirus
that infected CD4+ T lymphocytes that potentially caused the acquired immunodeficiency
syndrome (AIDS). These three prototype viruses , lymphadenopathy-associated virus
\-;
(LA V) (3), human T-cell leukemia virus II (HTL V-III) (4-7), and AIDS related virus
(ARV) (8), were closely related and identified as a lentivirus associated with AIDS (1).
This AIDS virus was later given the name Human Immunodeficiency Virus (HIV) in
1986.
HIV - l is the causative agent of the Acquired Immunodeficiency Syndrome
(AIDS). Currently, it is estimated that 39.4 million people are infected with HIV
resulting in 3. 1 million AIDS related deaths in 2004 with an estimated total of 20 milion
deaths due to AIDS since 1981 (9).
HIV - 1 infection can be segregated into three distinct phases (Figure 1. 1). Upon
contraction of the virus, an acute , primary infection develops. Primary infection often
correlates with a high viral burden and rapid loss of CD4+ T cells. This stage typically
lasts for several weeks as the virus-host interaction evolves. Initially, there is a burst of
viremia in the absence of an adaptive immune response. This rapid production of a high
titer of virus results in widespread cytopathicity as well as the establishment of a viral
reservoir. Within a few weeks of acute infection, the adaptive immune system mounts a
response and begins to control viral replication and spread. Once the immune system and
virus have found an equilibrium state , the viral setpoint is established and the disease
enters a latent phase (10- 13).
The hallmark of lentivirus infection is a latent phase that generally lasts five to ten
years with patients remaining asymptomatic during this period. The latent phase is
actually a phase of dynamic interaction between the virus and immune system. During
this time , the virus continues to replicate and induce cytopathicity. However, the
adaptive immune system is able to respond and prevent rampant spread of the virus. As
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the virus continues to replicate, it acquires mutations throughout the genome. The HIV-
RT enzyme is error prone and generally introduces one error per replication cycle. As
these mutations accumulate throughout the genome , naturally occurring escape mutants
are generated. These escape mutants are able to evade the host adaptive immune
response mediated by cytotoxic T lymphocytes (CTL) and begin to replicate rapidly (l4
15). This rapid spread of virus results in a precipitous decline in CD4+ T cells. A recent
study has mathematically determined that a typical host can withstand 1 300 viral years
before experiencing a complete depletion of CD4+ T cells (16), demonstrating a direct
connection between viral load and CD4+ T cell number. The loss of CD4+ T cells results
in the onset of the clinical manifestation known as AIDS (17-21). Once a patient has
entered the AIDS state , they will typically succumb to opportunistic infections resulting
in AIDS related death.
2. Long-Term Non-Progressors (LTNP)
Approximately 5- 10% of the mv - 1 infected population exhibit an aberrant
disease course (22). These individuals are asymptomatic for greater than ten years
maintain stable CD4+ T cell counts above 500cells//.l , and demonstrate strong immune
responses in the absence of antiretroviral therapy (23-28). When the CD4+ T cell counts
of L TNP from a hemophilia cohort are compared to slow progressors (SP), normal
progressors (P), rapid progressors (D), or seronegative individuals (SN), the profie
closely resembles that of HIV- l seronegative donors while all other HIV- l infected
groups show decline in CD4+ T cell counts over time (Figure 1.2). Typically, these long-
term non-progressors (L TNP) have low to undetectable viral loads and virus isolation
from these patients is often complex or unattainable (25 , 30). This low level of
Figure 1.
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plasma virus can be attributed to a number of factors including resistance factors in the
host or infection mediated by an attenuated strain of HIV - 1. In most cases , it is assumed
that a combination of an effective immune response and infection with a quasi species
containing attenuated virus is responsible for the remarkable disease course (30 , 31).
One host resistance factor is the CCR5 32 mutation (32 , 33). The CCR5
mutation is characterized by a 32-bp deletion that results in the expression of a truncated
CCR5 protein. Individuals who are homozygous for CCR5 32 do not properly express
the CCR5 chemokine co-receptor on the cell surface (33). Since the predominant HIV-
strains that are transmitted between individuals establish initial infection use CCR5 as a
co-receptor to enter the cell, the cell is protected from HIV infection by its lack of CCR5
on the cell surface. Homozygotes for CCR5 32 are rarely infected with mv - 1 (34-37).
However, since they remain susceptible to infection with strains of HIV - 1 that use the
alternate CXCR4 chemokine co-receptor to enter the cell, some rare instances of
infection have been detected (32 , 33 , 38-40). Additionally, heterozygotes for CCR5
are no less susceptible to HIV infection , but they do have delayed progression of disease
with a recent study showing that CCR5 32 heterozygotes have a 30% lower occurrence
of AIDS (38, 42). This protective effect could be attributed to detention of wild- type
CCR5 in the endoplasmic reticulum where it is complexed with the CCR5 32 protein
leading to decreased CCR5 density on the cell surface (43). Genetic polymorphisms in
the CCR5 promoter region may also deter HIV disease progression (44).
A second chemokine co receptor mutation , the CCR2- V64I mutation, has also
been implicated in retarded progression to AIDS (41 , 45). How this mutation contributes
to delayed progression is not understood.
There also exists a mutation in the stromal cell-derived factor- l (SDF- l) protein
that impacts binding of HIV- I to the CXCR4 co-receptor. SDF- I functions as the
primary ligand for CXCR4. A variant of this gene
, SDF- l 3' a, has a mutation in the
untranslated region that may allow upregulation of SDF- I expression. This creates an
environment where SDF- I is in abundance and can effectively compete with HIV- I for
binding to the CXCR4 co-receptor (44). SDF- I 3' a homozygotes demonstrate a delayed
progression to AIDS , but again there is no protective effect during initial infection where
CCR5 is the more important co-receptor (46
, 47).
Patient Human Leukocyte Antigen (.IA) types may also help define the rate of
disease progression. In general, .IA class I homozygosity at one or more of the HLA-
, HLA- , or HLA-C loci is associated with rapid progression to AIDS whereas
heterozygosity at at least one loci provides some protection and a delayed development of
disease (48-50). This could be explained by the diversity of antigenic peptides that can
be presented by heterozgotes versus the more limited repertoire presented by
homozygotes , which may curtail the appearance of CTL escape mutants (51).
Additionally, individual HLA alleles and haplotypes have discordant influence on disease
progression. The alleles B35 and Cw04 appear to expedite the development of disease
(48). Conversely, HLA B27 and B57 have most commonly been found in association
with long- term non-progression (52-56). When a cohort of L TNP were studied and
compared to progressors , it was found that 85% of L TNP, compared to only 9.5% of
progressors, had the 
.IA B*5701 allele , suggesting a protective effect for this allele
(57). A comprehensive study of HLA class I and II alleles identified HLA B 14 and C8 as
strong correlates of long-term non-progression (58).
---:;--:.- -- -
In addition to host factors that may manipulate the disease course, viral factors
can also playa role in sluggish disease development. If infection is mediated by an
attenuated strain of the virus , it may not be able to establish as robust an initial infection
or spread as effectively. It has been shown that the level of HIV - 1 in recent
seroconverters can be as low or lower than that in LTNPs. However, only LTNP are
capable of maintaining low levels of HIV - 1 replication , which impacts their development
of a long-term asymptomatic condition (59). Additionally, another study demonstrated a
direct correlation between in vitro replicative capacity of biological clones isolated from
long-term survivors (LTS) and in vivo viral load (60). A more recent study confirmed
this observation that the replicative capacity of L TN virus is significantly lower than
that of wild- type controls (61).
One of the first reports pertaining to the passage of a defective strain of mv - 1 in
a long-term non-progressing cohort was that of the Sydney Blood Bank Cohort (SBBC).
Deacon et al. reported the isolation of a HIV quasi species with deletions in nef and the
overlapping U3 region of the L TR that had been passed from a donor to multiple
recipients via blood transfusion (62). Both the donor and the recipients remained
asymptomatic for a period of at least ten years or more. However, the donor and some of
the recipients have shown progression to disease , perhaps due to the emergence of quasi
species with different nef genotypes (63). The SBBC report was in agreement with an
earlier report in which rhesus macaques were exposed to nef deleted Simian
Immunodeficiency Virus (SIV). The monkeys maintained stable CD4+ T cell counts and
low viral loads, indicating that nef was important for disease progression (64).
, '
A second early report on long-term non-progressors also implicated the nef gene
as a determinant of disease progression. An initial study identified a long-term non-
progressor who harbored a virus with a large nef deletion. Follow-up studies in the same
cohort revealed that an additional patient had only nef alleles with unusual
polymorphisms (65, 66). Observations relating to nef defective viruses and attenuation
continue , a second cohort in Australia consisting of three L TNP have been shown to
harbor virus carrying nef deletions (67).
The observation that nef defective virus was less infectious raised the question of
the contribution of other viral accessory genes to in vivo disease progression. While
there does not appear to be a common origin for attenuated H;IV- l viruses (68), many of
those recovered from LTNP do harbor mutations in the accessory gene region that range
from large deletions and premature stop codons to subtle , single amino acid changes.
The idea that accessory gene mutations playa critical role in viral replication can
be seen when viral isolates from LTNP are sequenced and analyzed. A study that directly
examined transmission of mutant genomes found that mother-to-child vertical
transmission did not occur when the mother had virus that carried vif and vpr mutations.
On the other hand , viruses from transmitting mothers were found to maintain a high
conservation of intact accessory genes (69). When the accessory gene region of vif, vpr
vpu, tatl , and revl were assessed for mutations in a single LTNP, 64% of the clones
carried missense or nonsense mutations (31 70). A cohort of Japanese hemophiliacs
revealed elevated levels of mutations in nef, vpu , vpr, vif, and rev-2 when compared to
progressors. Interestingly, vif had the highest rate of mutation with 36.7% in the LTNP
group and only 0.4% in progressors (71). In the recent Australian cohort study, one of
:')
the LTNP had viral sequences that revealed nef deletions in conjunction with mutations
resulting in expression of truncated Vif protein (67).
In agreement with the results above , several in vitro studies have provided data
implicating accessory gene defects in viral attenuation. In the monkey model
, attenuated
SIV constructs of multiple or single gene mutants were used to establish a ranking of
accessory gene mutations based on their contribution to replication from most attenuating
to "least attenuating- nef, vpx , vpr, US , v if:nef, vpx, vpr, US; vif: nef, vpx , US;: nef, vpr
US;:vpr, vpx; nef:vpx;:vpr (72). Also , the effect of mutations in nef, vpr, vpu , and vif
was assessed using mutated HIV- I in tissue culture assays. Vpu mutants showed an
impaired growth while vif mutants showed no detectable growth in both peripheral blood
mononuclear cells and macrophages (73).
While attenuating mutations in the accessory gene region diminish the replicative
capacity of the virus , they do allow the virus to establish an infection that is persistent. It
has been shown that mutants defective in vif, vpr, vpu , or a combination triple mutant
defective in all three of the central region accessory genes could establish a transient
infection with increased cytopathicity followed by a persistent infection with no
cytopathicity. These persistent viruses had acquired additional accessory gene mutations
that allowed for establishment of a long-lived, persistent infection as opposed to a short-
lived , highly cytopathic infection as seen in nefmutant or wild-type viruses (74). These
reports clearly establish that multi genic defects in the accessory genes, particularly those
of the central region (vif, vpr , vpu), can lead to a persistent, low- level infection that does
not lead to cytopathicity in the host.
While it is clear that multiple mutations working in concert can lead to highly
attenuated strains of HI V- , some single gene mutations can also be equally effective in
attenuating the virus.
The vpr gene has been implicated as a possible source of attenuation in L TNP.
Specifically, the R77Q substitution has been linked to long-term non-progression as 75%
of the identified LTNP in the Los Alamos National Laboratory (LANL) HIV database
have the R77Q substitution. It is proposed to playa role in reduced cytopathicity since it
resides in the (H(F/S)RIG)2 domain that has been linked to apoptosis , therefore leading to
less CD4+ depletion in vivo (75). Another report showed a correlation between non-
progression in spite of high viral loads and Vpr mutations. In this study, a L TNP with
stable CD4+ cells and high viral loads was found to have virus that contained vpr
mutations including early termination co dons and the unusual polymorphism, Q3R. It
was found that this Q3R mutation rendered the virus less cytopathic without disrupting its
replicative capacity (76). Again, it was proposed that the Vpr mutations were responsible
for decreased cytopathicity in the host, thus allowing for maintenance of stable CD4+
levels. A non-progressing mother-child pair also revealed only mutated vpr sequences at
amino acids 83- , as opposed to only wild-type sequences at 83-89 in people who had
progressed to AIDS, that potentially affect the ability of Vpr to induce G2 cell cycle
arrest, secondary structure of Vpr, and the overlapping tat gene (77, 78). These studies
indicate a potential role for Vpr in maintaining high levels of circulating CD4+ cells , even
when viral replication is not controlled , by disrupting the ability of Vpr to induce
apoptosis of infected CD4+ cells.
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The vif gene was actively investigated as it is known to influence HIV-
replication in vivo (73
, 79-81). In one study, a single amino acid difference was found to
distinguish LTNP from progressors (68
, 82). Non-progressors associate predominantly
with an Isoleucine at position 123 while a Threonine at the same position was found less
frequently in LTNP and in about half of the progressors studied. A second single amino
acid determinant was found to affect viral loads within the L TNP 
group and between the
L TNP cohort and the progressors. A Serine at position 132 was found in L TNP with 
low
viral load while an Arginine at 132 was associated with high viral load LTNPs or
progressors (82). A mother-child pair who both displayed LTNP characteristics were
studied for viral determinants of non-progression. In both the mother and the child
, a two
amino acid insertion in Vif was identified. This insertion mutant was studied for possible
attenuation of viral replication and it was found that viruses containing the mutant vif
gene were less infectious in vitro (83). A LTNP in a Japanese hemophilia cohort 
was
found to carry virus that had inactive vif in all clones sequenced (84).
While it is clear that accessory gene mutations contribute to viral attenuation
which in turn leads to delayed disease progression, one of the biggest questions
surrounding L TNPs is how the virus maintains those mutations in light 
of the high error
rate of the RT enzyme. Viral evolution is directly related to 
the amount of viral
replication occurring in LTNP. In LTNP with extremely low levels of replication
average of 275 copies HIV- l RNA/ml plasma , there is little detectable evolution of the
viral sequences. However
, L TNP with more moderate levels of replication
, average of
3420 copies HIV- l RNA/ml plasma, show an evolution from the ancestral sequences to
modern sequences. It is proposed that the LTNP who demonstrate this viral 
diversity and
evolution are actually slow progressors, while those that maintain ancestral sequences are
true long-term non-progressors (22).
C. Viral Life Cycle
A complex retrovirus , II V - 1 encodes the gag, pol , and env genes as well as the
accessory genes vif, vpr, tat, rev , vpu , and nef (Figure 1.3). The objective of HIV - 1 is to
enter the target cell , utilize the host cell machinery to generate viral transcripts , proteins,
and genomic RNA , and ultimately assemble and release progeny virions. Although
simplistic in its objective , the viral life cycle is extremely complex with extensive
interplay amongst viral proteins and to a greater degree, between viral proteins and host
cell factors (Figure 1.4). These interactions with host factors involve both the
exploitation of cellular proteins to perform functions necessary for completion of the viral
life cycle and the neutralization of inhibitory antiviral factors present in the target cell and
the host immune system.
The viral life cycle begins when the virion attaches to the target cell surface.
Initial binding is mediated by interaction of the viral surface glycoprotein gp120 to the
CD4 protein on the cell surface (85-87). Specifically, the fourth conserved region (C4) of
gp120 binds to the CD4 molecule (88 , 89). Conformation of gp120 at this binding stage
is critical as additional noncontiguous regions are also involved in contacting the CDR2
domain of CD4 (90), providing further support to the gp l20-CD4 anchor. The
importance of the gp 120-CD4 interaction has been confirmed by competitive binding
tests using soluble CD4 which leads to a loss of HI V- I infectivity (91-94).
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Following attachment of the virion to the cell surface via the gp120-CD4 binding
event , the gp120 co-receptor binding site becomes exposed as the env V1N2 loops
become repositioned (95). Once the binding site is exposed
, the V3 loop of env can
contact the chemokine cq-receptor on the cell surface.
There are a number of chemokine co-receptors for HIV - l entry. The two major
chemokine co-receptors are the CXCR4 co-receptor expressed on the surface of CD4
lymphocytes (96, 97) and the CCR5 co-receptor expressed on the surface of macrophages
(98- 10 1). The env V3 loop sequence determines viral tropism. HIV - 1 strains that bind
CXCR4 are classified as T- tropic , syncytium inducing (SI) strains. Those that bind
CCR5 are M- tropic , non-syncytium inducing strains (NSI). The V3 loop of X4- tropic
viruses is usually highly, positively charged. This is because the high positive charges on
the gp120 interact with the negatively charged E2 extracellular loop of CXCR4. This
electrostatic interaction helps to stabilize the gp120:CXCR4 interaction (95). For the R5-
tropic viruses , there is a lower net positive charge on the V3 loop.
Viral tropism plays a major role in disease progression as the initial infection and
asymptomatic phase are generally mediated by NSI strains (102- 104). The AIDS phase
generally develops following a switch in co-receptor use. This switch in tropism leads to
predominant use of the CXCR4 co-receptor
, therefore leading to an increase in the
number of infected CD4+ cells. This ability to broadly infect CD4+ cells leads to
depletion of the host CD4+ cell number and development of the clinical AIDS stage (105-
107). The importance of the R5 to X4 switch can be seen in the L TNP cohort as most
LTNP have R5- tropic , NSI viruses (108). In two studies
, it was shown that non-
progessors with nef-deleted virus who eventually progressed to AIDS underwent an R5 to
X4 tropic switch that correlated with disease progression (63 , 109).
The next step in the virus-cell fusion pathway is the exposure of the fusion
peptide in gp41. Since the gp 120 surface glycoprotein and gp41 transmembrane
glycoprotein are noncovalently linked , perturbing the gp 120 subunit results in a
conformational change that exposes the fusion peptide in gp41. The gp41 ectodomain
contains the fusion peptide as well as two regions , one N- terminal and the other C-
terminal , with heptad repeats. The fusion peptide inserts into the host cell membrane,
resulting in the pre-hairpin intermediate complex (110). The gp4l heptad repeats now
assume the fusion-competent arrangement of a six helix bundle (SHB) with the N-
terminal peptides assembling into three central helices surrounded by three helices
formed by the C- terminal peptides (111 112). The SHB hairpin structure can now draw
the viral and cellular membranes close together to allow for membrane fusion and entry
of the viral core. The formation of the six helix bundle is critical to virus entry. When
the SHB intermediate state is exposed to the peptide inhibitor T-20 that binds to the N-
terminal peptide region , it occludes the interacting sites for the C- terminal peptide. This
disruption prevents formation of the SHB and the virus cannot fuse to or enter the target
cell (63).
Once the virus fuses to the cell , the virion core is deposited into the host cell
cytoplasm. An il-defined uncoating process , which may involve phosphorylation of MA
to release the virion core from the plasma membrane (113), then occurs resulting in a
complex that is now competent for reverse transcription, the reverse transcription
complex (RTC). This RTC contains the necessary components to engage in the critical
step of reverse transcribing the encapsidated viral RNA genome into a double-stranded
DNA species that can be integrated into the host genome. The reverse transcription
process is a complex, highly regulated event that involves the use of the genomic RNA,
the virally encapsidated tRNA Lys3 primer, and the Reverse Transcriptase (RT) enzyme.
The RT enzyme catalyzes the entire process of reverse transcription (l14, llS).
The holoenzyme is composed of two subunits, a heterodimer of the p5l and p66 subunits.
The pSI subunit is derived from the p66 subunit by proteolytic processing, it does not
i,J
have RNaseH activity or a polymerizing cleft. The structure of the p66 subunit is often
described as a right hand with the palm containing the polymerase active site and the
template binding cleft formed by the palm, fingers, and thumb. The RNaseH domain is
tethered to the polymerase domain in the palm. The polymerase active site has three Asp
residues and two coordinated Mg + ions that are absolutely critical for polymerizing
;;1
activity. The template and dNTPs are trapped in the binding cleft by the fingers.
Following addition of the dNTP to the elongating chain , the fingers "relax" and open up
to allow for the next dNTP to enter for elongation to continue (116).
Since RT does not have exonuclease proofreading activity, it is prone to eITors
(117 , 118). The calculated mutation rate , including substitutions, frameshifts , deletions,
and deletions with insertions , is 3x 10-- mutations/cycle of replication (119). In addition
to the eITor prone RT enzyme , intermolecular jumps and intramolecular switches during
reverse transcription drive recombination. Also, the activity of the Apobec3G enzyme
can result in production of hypermutated genomes (120). Taken together, these changes
introduced during the reverse transcription process lead to rapid evolution of the viral
genome that may be important in generating immune escape variants (121 , 122).
The first step of reverse transcription is the annealing of the tRNA Lys3 primer to
the primer binding site (PBS) in the 5' termini of the viral RNA , a process directed by
NC and RT (Figure 1.5). Minus-strand DNA synthesis then proceeds from the 3' - OH of
the tRNA Lys3 primer towards the 5' end of the viral genome. This results in a RNA:DNA
duplex. RNaseH then degrades the RNA component of the duplex, thereby liberating a
short fragment of ssDNA known as the minus-strand strong-stop DNA. This ssDNA
encodes the R region that is homologous to the 3' end of the viral genome, which allows
hybridization of the minus-strand strong-stop DNA to the viral RNA template. This
hybridization is known as the first strand transfer.
Minus-strand synthesis occurs from the hybridization site at the 3' end towards
the PBS region at the 5' end. RNaseH continues to degrade the RNA from the resulting
RNA:DNA duplexes. However, short purine-rich sequences of RNA are resistant to
RNaseH degradation. These polypurine tracts (ppt) oligonucleotide binds the minus-
strand strong-stop DNA and serves as the primer for plus-strand DNA synthesis. Here,
the minus-strand DNA now serves as the template with the reaction proceeding toward
the 5' end of the minus-strand strong-stop DNA. This results in the production of a DNA
fragment known as the plus-strand strong-stop DNA consisting of the U3, R, and U5
sequences of the terminal region plus a segment of the PBS with elongation terminating
at position 19 of the tRNA Lys3 primer (123).
The tRNA Lys3 primer is degraded by RNaseH , exposing the PBS of the plus-
strand DNA. The plus-strand DNA can now engage in the second strand transfer reaction
where the plus-strand DNA hybridizes to its homologous region at the 3' end of the
minus-strand DNA. Plus-strand synthesis proceeds to the end of the minus-strand DNA
J .
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where it encounters the central termination signal downstream of the central ppt region
(124). The displacement of the plus-strand DNA 
at the central ppt results in a DNA
triplex , 99 nucleotides long, known as the flap that influences nuclear import of the viral
dsDNA (125). The integrity of the dsDNA is 
maintained by coating of the viral DNA
with the NC protein
, which is important for efficient integration into the host genome
(126- 129). Once the reverse transcription process has been completed
, the viral dsDNA
must be transported to the nucleus where it can be imported for integration in the host
genome.
The reverse transcription process is complex and error prone due to the infidelity
of the RT enzyme. In addition to this
, the RT reaction is also open to modifications by
cellular proteins. The function of Vif
, detailed later in this chapter
, is to indirectly protect
the RT process from attack by the protein Apobec3G. Apobec3G
, also detailed later in
this chapter, is a cellular cytidine deaminase that can package in the virion if Vif is absent
or non-functional in the producer cell. Apobec3G deaminates cytosine to 
uracil in single-
stranded DNA templates. Since there are a number of ssDNA 
species created during
reverse transcription
, the nascent viral transcripts are vulnerable to deamination by
Apobec3G. This deamination results in two potential outcomes. The first of which is the
creation of G-7 A hypermutations throughout the genome. This leads to the integration of
a defective provirus. Alternatively, the presence of uracil in 
DNA could activate cellular
DNA repair pathways that eventually lead to degradation of the DNA
, effectively halting
the reverse transcription process and ultimately the viral life cycle.
Fol1owing reverse transcription
, the large nucleoprotein complex consisting of the
linear dsDNA , the viral proteins MA
, RT, IN, NC , and Vpr, and the cellular protein
HMG I(Y) is now termed the Pre- integration Complex (PIC). This PIC must be directed
to the nucleus where it is actively imported to allow for integration of the viral dsDNA
into the host genome (130- 132). The lentiviruses are unique amongst retroviruses in that
. they are able to infect non-dividing cells by active transport through the nuclear pore
complex unlike other retroviruses, which must wait for nuclear envelope breakdown
during mitosis to gain access to the host chromatin.
The PIC undergoes size changes as it transits to the nucleus , thereby suggesting
that other viral and/or cellular proteins are associated with it, the MA, IN , and Vpr
proteins are considered to be critical for nuclear import. However , many studies have
shown conflcting results pertaining to nuclear localization of MA, IN , and Vpr as fusion
proteins. This has compounded efforts to elucidate the exact mechanisms involved in
nuclear import of the PIC. Whether one, all, or none of these proteins is invol ved in
nuclear import remains unclear, but it is clear that the HIV dsDNA genome does enter the
nucleus where it can undergo two events.
Following entry into the nucleus, the linear dsDNA can serve as a substrate for
two reactions. The first reaction results in a dead-end product and termination of the viral
life cycle. This reaction involves the formation of a circular form of the dsDNA driven
by ligation of the two ends to form a 2-LTR circle , formation of a l-LTR circle by
homologous recombination , or self- integration resulting in rearranged circles (133- 135).
The second reaction that can occur is integration of the linear dsDNA genome into the
host chromatin. This reaction leads to production of viral transcripts and continuation of
the viral life cycle.
The Integrase enzyme (IN) catalyzes the integration of the HIV - 1 provirus into
the host cell genome to allow for transcription of viral genes for production of virions and
propagation of infection to daughter cells. IN is composed of three domains, an N-
terminal domain containing the Zinc finger, a core domain , and a non-conserved C-
terminal domain. IN multimerizes, possibly mediated by the Zinc finger domain (136).
The core domain contains the D, 35-E catalytic triad motif that is responsible for IN
catalytic activity (137, 138). The C- terminal domain is capable of binding DNA (139), it
is necessary for 3' end processing of the provirus and is proposed to mediate IN
association with the provirus( l40).
Integration proceeds as a regulated , three step process (140, 141) First , 2-3nt are
removed form the 3' termini of the linear , proviral DNA. This step occurs while the pre-
integration complex is still in the cytoplasm. Once the provirus is in the nucleus , IN
cleaves the host chromosomal DNA resulting in processed 5' ends. The 3' recessed ends
of the proviral DNA can now be ligated to the cleaved 5' ends of the host DNA and the
provirus is integrated into the chromosomal DNA. The L TR regions have aft sequences
that mediate insertion into the chromosomal DNA (142). Finally, cellular DNA repair
mechanisms become activated to fil in the gaps resulting from the integration reaction
(140 , 14l , 143). A number of cellular cofactors have been identified that help to catalyze
the integration reaction including the non-chromosomal histone protein HMG I-a (144),
the SWI/SNF chromatin remodeling complex member Ini- l (145), the MA interacting
protein EED (l46), barrier to auto integration factor BAF (147), and most recently
LEDGF/p75 (148 , 149).
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Once the provirus has been successfully integrated
, the viral DNA can be
transcribed using the host cell transcription machinery. The long-
terminal repeat regions
created during reverse transcription contain cis elements that regulate viral RNA
synthesis. The 5' LTR contains the transcriptional promoter and 
regulatory regions while
the 3' LTR encodes the poly- A signal and addition site.
Transcription of the viral RNA is controlled much like transcription of cellular
RNA due to the fact that they use the same cellular machinery. The first step in viral
transcription is the binding ofTFIID to the TATA box located -
29 to -24nt upstream of
the transcription start site. TFIIB then binds the TFIID and acts to recruit the DNA
dependent RNA polymerase
, Pol II (150). The TAT A box plus three Spl sites constitute
the core promoter region. Mutating all three Spl sites can result in 
inhibition or delay of
virus production in some cell lines
, confirming the importance of these sites in
transcriptional activation (151
, 152). In addition to the core promoter
, there is an
enhancer region composed of two NF-KB sites upstream of the Spl sites. The NF-
and Sp 1 sites cooperate to promote binding 
of the transcriptional activators to the L TR
(153). If both NF-KB and all three Spl sites are eliminated
, no virus is produced (154
155). Additional regions downstream of the transcription start site including Ap-
like
DBF- l and Spl sites are responsible for maintaining an open chromatin region to
facilitate transcription (156
, 157)
Low- level , basal transcriptional activity can be driven by the binding of the
factors mentioned above to produce short
, abrogated transcripts. However
, the
processivity of Pol II is not optimal in this setting. Transcriptional activity is controlled
by the phosphorylation state of the Pol II compkx. Active transcription occurs when Pol
II is hyperphosphorylated. Initially, hypophosphorylated Pol II is recruited to the
transcription start site. It is this hypophosphorylated Pol II that drives the low- level
basal transcription. The Tat gene product is one of the short transcripts produced during
the basal activation period. Tat is translated in the cytoplasm and then imported back into
the nucleus via its nuclear localization signal. The HIV - 1 Tat protein recruits a CTD
kinase complex that drives phosphorylation at the C- terminal domain (CTD) of Pol II.
Tat is recruited to the site of transcription by binding to the HIV - 1 TAR RNA
element. The TAR element is unique as a transcriptional regulator as it is located
downstream of the transcription start site (158). TAR is derived from the first 59nt that
fold into a stable stem- loop structure. The minimal TAR element is comprised of a stem
region of base-paired nucleotides, a UCU bulge region, and a G-rich loop at the apex of
the loop structure (159). Tat requires the UCU bulge as well as the G-rich loop for
function.
Tat acts as a scaffold to recruit cellular factors that wil hyperphosphorylate Pol II
to enhance its transcriptional activity, this complex is known as the Tat associated kinase
(TAK) complex. Specifically, the cellular protein cyclin Tl binds the Tat activation
domain (160). Cyclin Tl serves two functions following Tat binding. First , it greatly
enhances the affinity of Tat for the TAR element as cyclin Tl binds to the TAR loop
region while Tat binds the UCU bulge (160- 162). Additionally, cyclin T1 serves to
recruit the cyclin-dependent kinase Cdk9 (160). It is the kinase activity of Cdk9 that
leads to hyperphosphorylation of the CTD of Pol II (163 , 164). This is the critical step in
Tat transactivation as hyperphosphorylated CTD allows Pol II to release from the
promoter and engage in processive transcription and active elongation of the transcript.
Following LTR driven transcription of the viral genes
, the viral transcripts must
be selectively exported out of the nucleus for translation. Typically, cellular transcripts
are subjected to post- transcriptional modification where introns are spliced out of the
transcript prior to nuclear export. However
, both the HIV genomic RNA and some of the
viral transcripts must be exported unspliced to allow for proper production of the viral
particle and viral proteins. The completely unspliced RNA serves 
as the genomic RNA
for packaging and also is the template for production of the Gag and Pol proteins.
Partially spliced transcripts encode the Vif
, Vpr, Vpu , and Env proteins. The initial
, fully
spliced transcription products that produce Tat also produce the Rev and Nef viral
proteins. Rev is analogous to Tat in that it is produced early during transcription and is
imported back into the nucleus to facilitate downstream processes in the transcription
pathway.
Rev is a nuclear-cytoplasmic shuttling protein that possesses an Arginine rich
nuclear localization sequence that drives nuclear import as well as a Leucine rich nuclear
export sequence that mediates export out of the nucleus. Rev functions by binding to the
Rev response element (RRE) present in all unspliced and partially spliced viral
transcripts. The RRE is a stem- loop structure found in the env gene. Initially, a single
Rev protein binds a purine rich bubble in stem loop II of the RRE. Then
, more Rev
molecules are recruited leading to multimerization and nucleation of the RNA (165-
168).
The Rev-RRE complex is then exported out of the nucleus by interaction with the
CRM- l nuclear export factor. Once Rev binds the importin-13 family member CRM-
CRM- l binds RanGTP and interacts with the nuclear pore complex to achieve nuclear
export of the unspliced RNA (169- 173). Nuclear translocation of the complex results in
the unspliced RNA being exported into the cytoplasm where RanGTP is hydrolyzed and
the complex dissociates , releasing the RNA for translation and production of viral
proteins that will assemble to form new viral particles at the cell surface (174
175).
Gag, Pol , and Env are all initially produced as polyprotein precursors. Gag and
Gag-Pol are translated by cytoplasmic ribosomes from the unspliced RNA while Env is
on a partially spliced transcript that is translated by ribosomes residing on the rough
endoplasmic reticulum. This leads to co- translational insertion into the lumen of the ER
and eventually Env transits through the Golgi. All three precursors must be present at the
cell surface for assembly and budding of infectious virions. Also
, all three precursors
must undergo proteolytic modifications to produce mature forms that are necessary for
viral infectivity.
Gao 
160Gao-Polag IS synt eSIze as a 0 po yprotem precursor or as a 
precursor as a result of a - 1 ribosomal frameshift (176). This frameshift occurs at a low
frequency due to a cis acting slippery sequence in the genomic RNA leading to a
Gag:Gag-Pol ratio of about 20: 1. The - 1 frameshift allows the ribosome to read through
the Gag stop codon and produce the Gag-Pol precursor. Maintenance of this ratio is
critical for infectivity to ensure that the Pol enzymes are present at appropriate levels in
the virion (177). Both precursors oligomerize and traffic to the inner side of the plasma
membrane. The trafficking of Gag and Gag-Pol is mediated by myristoylation of the N-
terminal Glycine residue in the MA region at the N-terminus of the polyproteins. Once
the polyproteins reach the surface
, a cluster of basic residues participate in membrane
binding by interacting with phospholipids in the lipid bilayer to stabilize the interactions
(178- 180).
Gag is composed of four domains, matrix (MA), capsid (CA), nucleocapsid (NC),
and p6. While MA directs trafficking to the cell surface , CA also plays a critical role in
forming the virion as the C- terminal dimerization domain is important for virion
assembly (181). In addition , the CA N- terminal core domain is responsible for virion
incorporation of the necessary cellular protein cycIophilin A (l82
, 183), recently shown
to provide protection against the host restriction factor Ref- l (184). The NC domain
contains two CCHC zinc fingers that are critical for genome encapsidation and
subsequent infectivity (185 , 186). The zinc fingers bind stem loop 3 of the Psi packaging
site located in the genomic RNA between the 5' LTR and gag genes (187). It is proposed
that NC acts as an adaptor molecule that binds the genomic RNA and the cytoskeletal
protein F-actin to promote trafficking to the cell surface (188- 190). Additionally, NC
actually nucleates the genomic RNA to promote dimerization of the two packaged RNA
strands (191 , 192). NC is important during the initiation of reverse transcription for
enhancing the annealing of the tRNA primer to the PBS (193 194). And, NC stimulates
strand transfers (195 , 196) and RT processivity during reverse transcription (197). The
p6 protein also serves multiple functions. A PTAP motif in p6 has been shown to be
necessary for virion budding and release (198, 199). Additionally, p6 recruits Vpr to be
packaged in the virion (200).
The Gag and Gag-Pol precursor polyproteins traffic to the cell surface by
usurping the cellular pathway normally involved in the creating of multi vesicular body
(MVB) vesicles in the late endosomal compartment. The p6 domain contains aPT AP
motif that recruits the cellular protein Tsg101 (201-203). TsglOl normally functions in
the cell to sort proteins into the MVB. The sorting of proteins into the MVB typically
involves the use of ubiquitin tags. The Gag proteins are monoubiquitinated at several
sites and ubiquitin is incorporated into the viral paricle, providing indirect evidence that
ubiquitylation is important for HIV budding (204, 205). Additionally, ubiquitin
mutations and application of proteasome inhibitors that deplete ubiquitin pools in the
cytoplasm can inhibit virus budding (206-209). Although the exact mechanisms of HIV
budding remain to be elucidated , it is clear that the interaction between the p6 PT AP
motif and Tsg101 and the involvement of ubiquitin are critical for proper trafficking of
the Gag polyproteins to the surface for assembly and budding.
The Env glycoproteins are initially produced as a gp160 precursor. The gp160
precursor is glycosylated in the ER. Also while in the ER, gp160 associates with
BiP/GRP78 , forms disulfide bonds, and oligomerizes, usually as a trimer (210, 211).
Once it enters the Golgi network, gp 160 is cleaved by a furin-like protease to yield the
gp120 SU and gp41 TM proteins (212). The gp120 and gp41 proteins are non-covalently
associated and are directed to the plasma membrane by the Golgi vesicles.
Env is recruited into rafts at the plasma membrane by two palmitoylated Cysteine
residues in gp41 (213). This recruitment increases the local concentration of Env at the
site of viral budding, leading to interaction with the Gag precursor and incorporation of
Env in the budding virion. The interaction of Env and Gag at the cell surface prevents
internalization of Env via the Y- L internalization motif by masking the motif (214-
216). MA directly binds the gp41 cytoplasmic tail to promote virion incorporation (217-
220).
Budding occurs at specific sites of the plasma membrane. In some cases
, this site
is known as the virological synapse as the release site is where cell-to-cell contact is
occurring. It is proposed that this directed release at the virological synapse provides the
virus with a direct route for passage to uninfected T cells. The site of virus release
typically occurs at lipid raft sites in the plasma membrane (2 13
, 22l , 222). Lipid rafts are
proposed to serve as platforms for recruiting the necessary viral and cellular proteins
involved in budding. This allows the budding machinery to concentrate at a specific site
to facilitate viral release.
The Gag-Pol precursor also contains the viral enzymes RT
, IN, and PR. The IN
domain of the Gag-Pol precursor has been shown to recruit the cellular uracil DNA
glycosylase (UNG2) enzyme into the budding virion (223). The packaging of UNG2 into
the virion is important for counteracting dUTP misincorporation into the genome during
reverse transcription. UNG2 can excise uracil bases from DNA and set off a DNA repair
pathway (224). Once the virion has assembled and budded from the host cell
, it
undergoes a maturation process directed by the PR enzyme. This maturation leads to the
evolution of a morphologically distinct particle that is fully infectious. PR is similar to
the cellular aspartic proteases with two Asp residues at the active site (225). HIV- 1 PR
functions as a dimer with the two monomers coming together to form flaps that surround
the binding site to help stabilize the substrate (226-229). The Asp residues lie in the
center of the dimer at the catalytic site. PR expression levels and function are tightly
regulated to insure that proper timing of PR activation occurs (230). PR must first
liberate itself from the Gag-Pol precursor by autocatalysis (231 , 232). Next, it engages in
an ordered series of proteolysis to free the components of the Gag and Gag-Pol
polyprotein precursors. Cleavage occurs to yield the p17 MA , p24 CA , p2 spacer, p7
- "'----"
, pI spacer, and p6 from Gag and the pII PR
, p66/p5I RTlRaseH
, and p3I IN
enzymes from the Pol region of Gag-
Pol (233).
While the object of the immature polyprotein precursors was to oligomerize
recruit additional viral or cellular proteins
, and target to the cell surface for virion
assembly and budding, the liberated
, mature forms of the proteins must now reorganize to
form a morphologically mature viral particle that is infectious (Figure 1.6) (234
, 235).
MA must interact to form the outer shell that underlies the lipid bilayer membrane. The
critical step in virion maturation is condensation of the core. The core is surrounded by
CA proteins and contains the two strands of positive sense RNA nucleated with the NC
protein as well as the RT/RNaseH
, IN, and PR enzymes. Once condensation of the core
is complete , the virion is now competent for infection of the next target cell. Any
mutations that disrupt the catalytic activity of PR and therefore perturb virion maturation
significantly reduce infectivity (236).
In addition to the Gag, Gag-Pol , and Env precursors
, the Tat, Rev , Vif, Vpr, Vpu
and Nef proteins are also translated and participate in early and late events in the viral life
cycle. Tat, Rev , and Nef are produced early in infection from the short
, fully spliced
transcripts. Tat and Rev are important for transcription and translation of the viral
proteins as described above. Nef participates in many phases of the life cycle. Vif
, Vpr
and Vpu are made from Rev-dependent transcripts later in the infection cycle.
Nef is a multi-functional protein that plays a role in many processes during the
viral life cycle and interacts with multiple cellular pathways. It is a small
, myristoylated
protein that binds membranes and is necessary for pathogenesis in vivo (64
, 237 , 238).
Nef, an early gene, is active in all stages of the viral life cycle including possible roles in
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transcriptional regulation (222 239), increased replication rates (240-242), increased
particle infectivity (243 , 244), immune evasion (245 , 246), and completion of reverse
transcription (247, 248).
Nef mediates the redistribution of both CD4 and Major Histocompatibility
Complex I molecules in infected cells. Nef redirects CD4 from the cell surface and Golgi
network to lysosomes where it is degraded (244 249). Nef interacts with the adaptor
protein (AP) complexes of the endosomal sorting machinery. This interaction leads to
transport of CD4 and Nef to lysosomes where degradation occurs (250). Downregulating
CD4 molecules increases the level of free Env available for virion incorporation on the
cell surface by preventing CD4-Env complexes from forming intracellularly, thereby
increasing the infectivity of released virions. Nef can also participate in immune
evasion by endocytosing or intercepting MHC I molecules in the Golgi , thereby
decreasing the expression of MHC I on the cell surface, which reduces susceptibility of
virus infected cells to recognition and kiling by cytotoxic T cells (245, 246).
Interestingly, although these processes of CD4 and MHC I downregulation both involve
the use of AP complexes and endosomal sorting pathways, they are mediated by distinct
motifs in Nef, the dileucine C-terminal motif for CD4 downregulation and an acidic
cluster for MHC I downregulation (245 , 250-253).
Nef is also important in infected macrophages. Here, Nef stimulates the release
of CC- chemokines MIP- l oc/ that act as chemotactic agents to recruit T cells to the
infected macrophage. The recruitment of uninfected T cells to a site of high virus
production allows for efficient infection of the substrate T cells (254). Not only does Nef
mediate recruitment of substrate T cells , but it can also induce macrophages to produce
soluble factors that allow resting, quiescent T cells that are ordinarily refractory to HIV
infection to become permissive for infection. Nef does so by intercepting the CD40
signaling pathway and activating NF-KB to induce the secretion of soluble CD23 and
ICAM. Both sCD23 and sICAM stimulate B cells to upregulate co-stimulatory
molecules that in turn drive resting T lymphocytes out of G(O) of the cell cycle and allow
them to become permissive to infection by HIV- 1 (255).
Another interesting feature of Nef is its presence in the virion (256, 257). Virion
associated Nef is important for infectivity as Nef defective virions show decreased levels
of viral cDNA synthesis (247 248). One study has shown that Nef is associated with the
mature core following CA dissociation (258). Other studies have suggested possible
roles for Nef in proper disassembly of the core prior to initiation of reverse transcription
(259) or enhancement of RT affinity for the RNA substrate (260).
The viral protein U (Vpu), encoded only by HIV - 1 (261 , 262), also participates in
CD4 downregulation (263) and enhancement of viral particle release from the cell surface
(264 265). Vpu is a small , oligomeric , integral membrane phosphoprotein. It
participates in CD4 degradation in the endoplasmic reticulum to liberate Env from CD4-
Env complexes. These CD4-Env complexes retain Env in the ER until Vpu degrades the
CD4 , which allows Env to proceed to the cell surface. Vpu binds the CD4 and the
cellular protein h- TrCP simulataneously. The complex is directed to the proteasome via
Skp1 and the F box motif on h- TrCP (266). A recent study has shown that Vpu acts 
promote viral release by interacting with the K+ channel TASK- I. Here , it was shown
that V pu has regions of homology to TASK- I. This homology allows V pu to bind
T ASK- l as it multimerizes to form a K+ channel. Intercalation of Vpu into T ASK-
-1 -
channels disrupts the current of the channel and leads to changes in the membrane that
allow for enhanced release of HIV - 1 virions from the cell surface (267).
The Vpr protein of HIV - 1 is a small , basic protein that is critical in the
pathogenesis of AIDS (268). Much like the Nef protein
, Vpr is a multitasker that
functions throughout the viral life cycle and is packaged in the virion. The incorporation
of Vpr is controlled by its interaction with the p6 protein in the Gag precursor (200).
Once the virion has undergone maturation , Vpr associates with the genomic RNA in the
virion core (256 , 269, 270). Following entry and uncoating, Vpr remains associated with
the RTC and the PIC post-reverse transcription (271
, 272). It has also been shown that
Vpr indirectly affects the fidelity of the reverse transcription process by recruiting the
cellular DNA repair enzyme uracil DNA glycosylase (UNG2) to be packaged in the
virion (119, 273 274). Within the RTC , UNG2 functions to suppress the mutation rate of
the error-prone RT by excising uracil from DNA. Vpr directed UNG2 incorporation
remains open to debate as other groups have shown that it is the IN domain of the Gag-
Pol precursor that directs UNG2 packaging (223 224).
PIC associated Vpr could be important in mediating nuclear import of the viral
DNA (275, 276). Vpr may playa role in the docking of the PIC with the nuclear
envelope , rather than the actual translocation process (277 278). The virion packaged
Vpr is also able to induce G2 cell cycle arrest by inactivating p34/cdc2-cyclinB kinase
(279-282). It is believed that this provides a favorable environment for viral transcription
since the HIV- 1 LTR is more active in G2 (283). Vpr has also been shown to
transactivate the viral LTR through the NF-KB
, Spl , C/EBP, and GRE enhancer
sequences in the promoter region (284-286). In addition to L TR activation , Vpr directly
- --- - - - . - - -
interacts with the transcription factor TFIIB-
, which is part of the basal transcription
machinery (287).
In addition to the virion incorporated Vpr
, the newly synthesized Vpr also plays a
role in the infected host cell. Vpr is a 
pro-apoptotic protein and is believed to induce
death , which may contribute to CD4+ depletion in vivo (76
288). Two divergent
viewpoints on how Vpr induces cytotoxicity exist. One suggests that apoptosis is a
byproduct of the G2 cell cycle arrest by aberrantly activating cdc2 (289) or the A TR
pathway (290). The alternate pathway 
involves Vpr disrupting the mitochondrial
membrane leading to release of cytochrome c
, which then activates the caspase pathway,
and pro-apoptotic factors into the cytoplasm (291
, 292). Vpr crosses the outer
mitochondrial membrane and then interacts with the adenine nucleotide translocator
, atransmembrane protein on the inner membrane
, to induce membrane permeabilization
and release of apoptotic factors (292
, 293).
D. HIV-J Vifand Apobec3G
1. Background
The viral infectivity factor (Vif) protein ofHIV-
1 is critical for infectivity in vivo
as well as in certain non-permissive T cell lines such as H9
, HUT78 , and CEM.
However, Vif is dispensable in the permissive T cell lines SupTl
, Jurkat, and CEM-
(73 79- 294- 296). Vif is a 27kDa protein that is present in the cytoplasm. It has been
shown to associate with the cytoskeletal protein vimentin
, the P 55Gag precursor
, and the
viral RNA genome.
Early experiments aimed at elucidating the function of Vif utilized heterokaryons
I H
to determine if non-permissive cell lines encoded a restrictive factor
, or if permissive
lines provided a homologous protein that could substitute for Vif. The result 
of the
heterokaryon experiment suggested that non-permissive cell lines express a restrictive
factor that Vif must counteract (297).
Sheehy et al. performed genetic screens on the non-permissive cell line CEM and
compared it to the related , permissive cell line CEM-SS to identify the candidate
inhibitory protein , which they termed CEMI5. They went on to show that CEM15 is
differentially expressed in non-permissive cell lines , but not permissive cell lines.
Exogenous expression of CEM15 in permissive cell lines was sufficient to render them
non-permissive (298). It was later revealed that CEM15 is actually the apolipoprotein B
mRNA editing catalytic polypeptide 3G (Apobec3G) (299). Apobec3G is a cytidine
deaminase that deaminates cytosine to uracil in single-stranded DNA (300
, 301).
Subsequent experiments revealed that in addition to Apobec3G, the related family
members Apobec3B and Apobec3F also demonstrate antiviral activity against HIV-
(302-305).
2. Apobec3G
The Apobec superfamily consists of Apobec 1
, Apobec2 , Apobec3A- , and
activation induced deaminase (AID) in humans. Each of these family members
deaminates cytosine to uracil in either an RNA or DNA template. All members have at
least one catalytic site with a zinc-dependent cytidine deaminase domain of HXEX
PCXXC, while Apobec3B/F/G have undergone gene duplication to produce larger
proteins with two catalytic sites (299).
Apobec3G is expressed in lymphoid and myeloid cell lines. It is not
constitutively expressed , but rather its transcription is regulated by an inducible
PKCa/ I/MEK/RK pathway that can activate downstream transcription factors. This
protein kinase cascade can be induced by treatment with the phorbol ester PMA. T cell
activation , but not HIV- 1 infection , upregulates Apobec3G expression (306). Apobec3G
is expressed exclusively in the cytoplasm of cells, possibly to avoid editing of
endogenous DNA (307). Evolutionary studies of the Apobec3G gene in non-human
primates and hominids suggests that a positive selective force was exerted on the gene
prior to the emergence of modern lentiviruses. It is proposed that Apobec3G initially
evolved to target endogenous retroviruses in humans (HERV), and only later became an
antiviral factor directed against HIV as well as hepatitis B virus (307).
Early studies revealed that Apobec3G is incorporated into virions in the absence
of Vif (308, 309) via an interaction with the NC domain of the Pr55Gag precursor (310-
313). Gag alone , in the absence of viral proteins and genomic RNA , is sufficient for
packaging Apobec3G into virus like particles (VLP) (311
, 313 , 314). Although it was
shown that binding is mediated by the first eleven residues in the N- terminus of NC and
the first linker region of Apobec3G (311 , 312), the ability of divergent Gag molecules
from ML V, SIV , and different IlV subtypes to efficiently package Apobec3G suggested
that there was not a direct interaction between the two (312). Subsequent work revealed
that there appears to be an RNA bridge that facilitates the interaction of NC and
Apobec3G in the cell (313 , 315). One recent study showed that Apobec3G is mono-
ubiquitinated by Nedd4- 1 and that this modification may address Apobec3G to a
compartment where Pr55 Gag precursor is also present (310, 316). Apobec3G has been
found at the cell surface as an aggregate with Gag as well as in late endosomal
-1.
compartments where Gag is present (297). These studies have led to a model where
Pr55Gag precursor interacts with Apobec3G via cellular RNA in specific compartments of
infected cells. This interaction allows the NC domain of PrSSGag precursor to direct the
packaging of Apobec3G into the budding virions.
The objective of Apobec3G is to associate with the viral core so that it can enter
the target cell and remain associated with the RTC. Exploiting an interaction with NC
guarantees passage into the virion core. Once in the RTC in the target cell, Apobec3G
can utilize the minus strand DNA produced during reverse transcription as a template for
cytosine deamination (Figure 1.7). Apobec3G wil deaminate cytidine to uracil on the
minus strand cDNA (120, 122 301 308 317). The presence of uracil in DNA typically
sets off a pathway that results in degradation of the uracil containing DNA. This would
explain the observed defect in /) Vif virions where reverse transcription is either
incomplete or the transcripts are unstable (318 , 319). Alternatively, the presence of uracil
in DNA could trigger a pathway that recruits the cellular repair enzyme uracil DNA
glycosylase to excise the uracil , leaving an abasic site in its place. Since the RNA is
degraded rapidly during reverse transcription by RNaseH , there is no template available
to repair the abasic site. So, HIV - 1 RT will preferentially insert an adenine across from
an abasic site. The end result of cytidine to uracil deamination is a G- to-A mutation in
the coding, plus strand of the viral DNA. Apobec3G has a preference for GG
dinucleotides, usually in the consensus sequence T/A GG where the is mutated to an
A (320). While this explained most of the G-to-A hypermutation that was detected in the
HIV - 1 genome following reverse transcription , it was the identification of Apobec3F as
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an antiviral factor that helped to explain the additional G- to-A mutations that were
frequently detected in sequences that were not Apobec3G targets. Apobec3F functions in
a manner analogous to Apobec3G , but its preference for target nucleotides is the cytidine
in the context of TC dinucleotides (302). Hypermutation of the genome often leads to the
generation of premature stop codons such that provirus that is integrated is attenuated or
completely defective (301)
Apobec3G contains two cytidine deamination (CD) sites. The N-terminal CD 1
site is involved in RNA binding, virion incorporation , and antiviral activity while the C-
terminal CD2 site is responsible for cytidine deaminase activity and the editing mediated
antiviral effect (321) Either of these sites is capable of exerting an antiviral effect
suggesting that while editing of the genome wil inhibit the viral life cycle , Apobec3G is
capable of impacting the reverse transcription process in other manners (322).
Interestingly, it has been shown that Apobec3G inhibition of hepatitis B virus is
independent of the deamination activity of Apobec3G, supporting the idea of a second
. i
antiviral effect that supplements the hypermutation induced by cytidine deamination
(323). It was recently demonstrated that the enzymatic activity of Apobec3G is critical
for its antiviral activity, but it is not the only determinant. Deletion mutants that were
impaired for DNA editing activity maintained an ability to inhibit HIV infection (324). It
is possible that this secondary antiviral effect is the result of Apobec3G interaction with
NC. The hallmarks of !1 Vif virions are defects in intravirion reverse transcription and
endogenous reverse transcription (318 , 325). One study also showed that !1 Vif virions
undergoing reverse transcription had compromised capacity for proper tRNA placement
(326), although a second study shows limited defects in the endogenous RT assay for
11 Vif virions (327). NC is necessary for the production of full-length reverse transcripts
and is involved in placement of the tRNA primer on the PBS. Therefore , it is possible
that the interaction of Apobec3G with NC , in the absence of Vif, results in packaging of
Apobec3G and downstream disruption of NC function during subsequent reverse
transcription.
3. HIV- l Vif
Clearly, packaging of Apobec3G into the virion is suicide for the virus.
Therefore , the virus utilizes its Vif protein to neutralize Apobec3G inhibition by
preventing its incorporation into the virion (309, 328, 329) . The ability of Vif to prevent
virion incorporation of Apobec3G packaging is critical as 11 Vif viruses are defective in
post-entry events in the life cycle due to the presence of Apobec3G in the virion. Once
Apobec3G has been encapsidated into the virion, it can inhibit the reverse transcription
steps, even if Vif is also present in the virion (330). Initially, it was shown that Vif
mediates Apobec3G degradation via the proteasome pathway to reduce available
Apobec3G for packaging (329, 331-333). Additional studies have also pointed to the
ability of Vif to block Apobec3G packaging by direct interaction and sequestration of the
protein away from NC and the virus assembly site (334 , 335).
Initial studies looking at Vif neutralization of Apobec3G were focused on the
active degradation of Apobec3G promoted by interaction with Vif. When intracellular
expression levels of Apobec3G were compared in cells infected with a WT or 11 Vif virus
the levels were consistently much lower in the presence of WT Vif. Also , when these
cells were treated with proteasome inhibitors, this Apobec3G downregulation could be
partially rescued (329, 331-333). Additionally, it was found that Apobec3G is subject to
modification by polyubiquitination in the presence of Vif. This led to the conclusion that
Vif directs Apobec3G degradation via the cellular proteasome pathway (331-333).
While the above studies suggested that Vif and Apobec3G might directly interact
to drive Apobec3G degradation , the mechanism by which Vif actively promotes
proteasomal degradation was defined in a series of papers examining Vif interaction with
the Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex (Figure 1.8). The first
observations indicated that Vif intereacts with Apobec3G and the Cul5 pathway to
promote degradation of Apobec3G. The nonfunctional SLQ Vif mutant was stil
competent for Apobec3G binding, but not Cu15 interaction , suggesting that Apobec3G
binding alone was not sufficient for proteasomal degradation of Apobec3G (336).
Building on this data plus a previous observation that the highly conserved and critical
SLQ motif in Vif resembles a SaCS-box motif (332), the Yu group went on to show that
Vif assembles with Cul5 via a novel SOCS box motif. Here , it was shown that Vif
utilizes its atypical SLQ sacs box motif to interact with Elongin C. Elongin C then
serves as a scaffold for recruitment of Elongin Band Cul5 along with Rbx 1 and an E3
ubiquitin ligase. In addition to the SOCS box motif, upstream Cysteine residues at
positions 114 and 133 in Vif are critical for stabilizing the Vif-Cul5 complex (337) The
assembly of the Vif-Cul5 complex is subject to regulation by phosphorylation. Also
when Vif assembles with Cul5 , both Vif and Apobec3G are ubiquitinated by the E3
ubiquitin ligase (338). Finally, an in vitro assay was developed to confirm that
Apboec3G could serve as a substrate for the Vif-Cul5-E3 ubiquitin ligase complex (339).
This suggests a model where Vif interacts with the Cul5 complex and recruits Apobec3G
Figure 1.8
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to the complex for polyubiquitination. This would then target both Vif and Apobec3G to
the proteasome for degradation.
While it is clear that Vif can mediate direct degradation of Apobec3G via
recruitment of an EloBC-CuI5-E3 ubiquitin ligase complex , several studies noted that
blocking this pathway did not restore Apobec3G levels completely. Therefore
, it was
suggested that Vif has a second function that does not involve the proteasome pathway
for Apobec3G inhibition. Mehle et al. proposed that Vif regulation by phosphorylation
could indicate the existence of an alternative
, phosphorylated form of Vif that could stil
bind Apobec3G , but might sequester Apobec3G in a distinct subcellular comparment
rather than direct its degradation (338). To further explore this idea of an alternative
pathway for Apobec3G neutralization by direct binding in the absence of degradation
, a
study was performed in E. coli cells that lack proteasomal machinery. In this study, Vif
and Apobec3G were both expressed in E. coli and Apobec3G cytidine deaminase activity
was monitored by following cytidine deamination in an Apobec3G substrate template. It
was found that in this system, Vif tightly binds Apobec3G and this is sufficient to
decrease Apobec3G deaminase activity. Previous work had established that a D128K
mutation in Apobec3G does not disrupt its catalytic activity, but renders it resistant to
HIV- l Vif (340-343). The Vif induced inhibition of Apobec3G catalytic activity could
be alleviated by using D128K Apobec3G
, confirming that Vif-Apobec3G interaction is
sufficient to inhibit Apobec3G activity (335). Also in support of a supplemental antiviral
effect by interaction in the absence of degradation
, Kao et al. has shown that Vif and
Apobec3G can be efficiently co-expressed in cells and that virus produced from these
cells is infectious (334). Taken together
, this data indicates the existence of two distinct
pathways that Vif can exploit for Apobec3G inhibition. This is not unique as the MDM2-
p53 interaction in cells can be disrupted by two separate
, independent mechanisms under
different conditions (344).
It is clear that Vif functions to prevent virion encapsidation of Apobec3G. This
can be achieved by two mechanisms
, either directed degradation of Apobec3G by a Vif
induced EloBC-CuI5-E3 ubiquitin ligase complex or by the direct engagement of
Apobec3G by Vif. Since both of these 
approaches are necessary, but not sufficient for
prevention of Apobec3G into virions
, Vif probably utilizes both of these approaches
simultaneously in the cell to ensure that Apobec3G is not available for interaction with
NC and packaging into the virion. Once in the virion
, Apobec3G can exert its antiviral
effects by either directly modulating NC or inducing hypermutation of the nascent viral
reverse transcripts leading to abortive reverse transcription or the generation of
hypermutated
, defective genomes.
In addition to the recently derived knowledge of Vif function
, many studies have
been performed to address the subcellular localization of Vif in an effort to understand
how this might contribute to Vif function. Early work in the field of Vif subcellular
localization revealed that Vif is a predominantly cytoplasmic protein that shows diffuse
staining throughout the cytoplasm as both a soluble and membrane associated protein
(345-347) Other studies suggested cytoplasmic colocalization of Vif with the HIV Gag
protein , perhaps mediated by the NC domain of Gag (348-
350). In addition to the noted
cytoplasmic localization of Vif
, it has also been reported to form vimentin caged
perinuclear aggregates in some cells (348
, 351 , 352). Functionally, it was found to be
critical for Vif to localize to both an insoluble and soluble cytoplasmic fraction. Viruses
harboring mutant Vif proteins that localized only to the soluble fraction were rendered
significantly less infectious (353) Most of these studies were performed in permissive
Helaor 293T cells prior to the identification of Apobec3G as the cellular target for Vif
function. As such , they were unable to provide a correlation between subcellular
localization of Vif and Apobec3G neutralization by Vif. Two recent studies have shown
that cytoplasmic localization of Vif is absolutely critical for Viffunction (352 , 354). The
need for Vif in the cytoplasm is obvious when its fl1nction is considered. Vif interacts
with Apobec3G, a cytoplasmic protein , and sequesters it in a cytoplasmic compartment or
drives its degradation via the cytoplasmically located proteasome pathway. Also , the
observations that Vif and Gag colocalize and that this colocalization may be mediated by
NC can now be better understood when Apobec3G is considered in the equation. Vif
must prevent Apobec3G from binding NC and packaging in the virion. Therefore, Vif-
Gag colocalization may be important for preventing NC interaction with Apobec3G by
direct occlusion of the Apobec3G binding site on NC or by competitive binding of
Apobec3G by Vif.
In summary, much work has been done in the Vif field recently. Several studies
have provided insight into the cytoplasmic localization of Vif. Many recent works have
dissected the function of Vif in counteracting the cellular cytidine deaminase Apobec3G.
Taken together, we can now consider a model for Vif where it interacts with Apobec3G
in the cytoplasm to neutralize Apobec3G. This interaction may occur by two distinct
pathways involving active degradation or sequestration that may function synergistically,
or under different physiological conditions. Regardless of the pathway, the ultimate
objective of Vif is to prevent Apobec3G from interacting with the NC domain of the Gag
precursor and packaging into the virion. Once Apobec3G has packaged in the virion
, it is
capable of exerting an antiviral effect by inducing cytidine deamination of the nascent
retroviral transcripts, or perhaps by influencing other components of the reverse
transcription machinery leading to abortive reverse transcription or the production of
hypermutated , dead-end viral genomes.
E. Thesis Aims
The objective of this thesis was to determine the impact of Vif subcellular
localization on function. The recent insight into the Vif-Apobec3G interaction and its
contribution to the replication status of virions has demonstrated the critical nature of the
Vif protein. While many studies have aimed at elucidating the mechanism by which Vif
degrades Apobec3G, here the goal was to determine where Vif encounters Apobec3G
and how altering the subcellular localization of Vif might disrupt its function by
preventing a Vif-Apobec3G interaction.
In Chapter II, the initial studies pertaining to Vif subcellular localization are
presented. Here , the importance of Vif localization was derived by investigating a
naturally occurring Vif mutant present in the virus isolated from a unique long-
term non-
progressor. The Vif protein from this L TNP was non-functional and contributed to the
low viral growth phenotype observed in tissue culture assays. The amino acid sequence
of this Vif mutant revealed a unique set of mutations at the central region of 9o
KKRK93
This KKRK motif was found to be a functional nuclear localization sequence that
mislocalized Vif from the cytoplasm to the nucleus. Isogenic clones of NL4.3 that
differed only at the central region revealed that NL4.3/KKRK virus was significantly less
i- 
infectious than NL4.3/WT virus when produced from non-permissive cells. These
findings suggested that the presence of a functional Vif in the cytoplasm is necessary for
production of infectious virions.
Based on the above observations , the NL4. 3/KKRK mutant was further
characterized to determine its capacity for Apobec3G neutralization. In Chapter IV, it is
shown that NL4. 3/KKRK Vif is less capable of interacting with Apobec3G in the cell
although in vitro binding assays reveal that it is fully competent for Apobec3G binding.
Additionally, data are presented that demonstrate a diminished capacity for NL4. 3/KKRK
Vif to downregulate Apobec3G by degradation or sequestration. Also, it was found that
Apobec3G was efficiently packaged into the NL4.3/KKRK virion , but not the NL4.3/WT
virion. This study is the first to show an aberrant interaction between a naturally
occurring Vif mutant and Apobec3G leading to Apobec3G virion encapsidation and
decreased virus infectivity. Additionally, it highlights the importance of Vif cytoplasmic
localization in inhibiting Apobec3G virion packaging.
Chapter V builds upon the above findings to further investigate the role of
NL4. 3/WT Vif in the cytoplasm of infected cells. Initial studies suggested that Vif
functions by directing the degradation of Apobec3G by exploiting the EloBC-Cu15-
ubiquitin ligase to ubiquitylate Apobec3G for degradation by the proteasome. However
we and others have observed conditions where Vif is stil capable of inhibiting
Apobec3G in the absence of complete degradation. This suggested a second pathway for
Vif neutralization of Apobec3G. Work presented here shows that Vif can also inhibit
Apobec3G by sequestering it into a perinuclear aggregate. To accomplish this , we prove
that Vif can exploit the cellular aggresome pathway to recruit Apobec3G into an
aggregate. This would effectively prevent virion packaging of Apobec3G by
sequestering it at a perinuclear site distant from the virus assembly and budding site.
Disruption of aggresome assembly leads to decreased infectivity of virions produced in
from cells expressing Apobec3G. This alternative pathway would serve as a parallel
mechanism for Apobec3G inhibition in conjunction with the previously demonstrated
proteasome pathway.
The data presented here confirm that cytoplasmic localization of Vif during the
viral life cycle is critical. Additionally, evidence of a second pathway for Vif mediated
Apobec3G neutralization is presented. These findings could influence both vaccine and
therapy design as abrogating Vif function leads to inhibition of viral replication as well as
having an impact on the Vif biology field by defining alternate pathways for Vif
mediated Apobec3G neutralization.
CHAPTER II
MATERIALS AND METHODS
A. Subject
Long-Term Non-Progressor 4 (LTNP4) is an HIV- 1 seropositive hemophiliac.
L TNP4 has been followed as part of the New England Hemophilia Center cohort since
1983. LTNP4 is also hepatitis Band C seropositive. The patient was infected with HIV-
1 via infusion with contaminated factor VIII concentrates prior to 1984. LTNP4 is
antiretroviral therapy na'ive.
B. Immunological Assays
CD4+ and CD8+ T cells were enumerated by labeling whole blood with
fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated mouse monoclonal
antibodies (Becton Dickinson , Mountain View , CA) and analyzing by fluorescence-
activated cell sorting (FACS). CD4+ and CD8+ T cells counts are presented as cells/!!l.
CD4+ T cell counts were monitored semi-anually from 1983 to the present. CD8+ T cell
counts were derived annually as were CD4+/CD8+ ratios.
C. Quantifcation of Plasma Viral Load
Plasma viral load was determined by quantitative PCR using the Amplicor HIV-
Ultrasensitive Monitor Test, according to manufacturer s instructions (Roche
Diagnostics, Branchburg, NJ). Plasma samples were processed and viral RNA was
amplified using the reverse transcriptase polymerase chain reaction (RT-PCR).
Amplified products were quantified by comparison to a standard panel of known HIV-
RNA copy numbers. Results presented in Chapter In are HIV- 1 RNA copies/ml. The
limit of detection for the assay was improved from 400 copies/ml to 50 copies/ml in
1997.
D. Cell culture and co-culture assays
All parental T cell lines were cultured in RPMI media supplemented with 10%
FBS at 37 C in a humidified 5% CO incubator. Vif-complementing T cell lines (kindly
provided by Dr. Dana Gabuzda, Dana Farber Cancer Institute) were maintained as above
with the addition of puromycin at 1I-g/ml. The permissive SupT1 cell line, as well as the
non-permissive H9 and HUT78 cell lines, and their Vif-complementing derivatives were
used in infection and co-culture studies presented in Chapter 3. The paired cells lines
CEM, the non-permissive , parental line , and CEM-SS, a CEM derived , permissive line,
were used for infection studies presented in Chapter V.
The adherent Hela cell line was cultured in Dulbecco s modified Eagle medium
(DMEM) supplemented with 10% FBS. The Hela derivative MAGI was cultured in
DMEM/lO% FBS plus 2001-g/ml G4l8 , and 100l-g/ml Hygromycin B. The GHOST-
reporter cell line , an adherent cell line that are stably transfected to allow constitutive
expression of CD4 and CXCR4 and that harbor the GFP protein under the control of the
HIV- 1 Tat promoter, was cultured in DMEM supplemented with 10% FBS plus 11-g/m1
puromycin , 5001-g/ml G418, and 50l-g/ml hygromycin B. Hela-Apo lines are Hela cells
stably transfected with an Apobec3G expression vector. Lines are main tainted in DMEM
supplemented with 10% FBS under selection with 400f.g/ml G418.
Blood from both HIV seronegative and seropositive individuals were collected
and peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Paque
(Amersham Biosciences , Piscataway, NJ) density gradient centrifugation. PBMC were
stimulated with phytohemagglutinin (PHA) at 5)lg/ml for 3 days followed by CD8+ T cell
depletion by magnetic beads coated with an antibody specific for CD8 (Dynal , Inc , Great
Neck , NY). PBMC were cultured at 2x10 cells/ml in RPMI supplemented with 10%
FBS , lOU/ml rIL- , penicilln G (100U/ml), and streptomycin (lOO)lg/ml) (all cell culture
reagents from Sigma-Aldrich , St. Louis, MO except for rIL-2 from Roche Applied
Diagnostics , Indianapolis , IN). Co-cultures were performed according to the AIDS 
Clinical Trial Group (ACTG) virology lab manual protocol for isolating LTNP virus by
co-culturing L TNP PBMC with normal , seronegative donor cells.
For growth of LTNP4 virus presented in Chapter III, a modified co-culture
technique was developed for co-culture of patient cells with T cell lines. CD4+ T cell
enhanced LTNP4 PBMC were re-stimulated overnight with PHA(5)lg/ml). 2x10
patient cells were co-cultured with 2x 1 0 cells of the parental or Vif-complementing T
cell lines and maintained in RPMI/1O% FBS supplemented with 1OU/ml recombinant
interleukin 2 in a 12-well culture plate. One week post-co-culture, cells were switched to
RPMI/lO% FBS for the parental T cell lines and RPMI/lO% FBS supplemented with
1 )lg/ml puromycin for the Vif-complementing Tcelllines. For co-culture of transfected
cells with T cell lines , 2x 1 0 parental or Vif complementing HUT78 cells were washed
once in RPMI/l0% FBS and then added to 2x transfected HUT78 cells in a 24 well
plate. All cell cultures were incubated at 37 C in a 5% CO humidified incubator.
Culture supernatants were assayed for virus production by RNA PCR and p24 antigen
detection assays every 3 to 4 days post-co-culture.
E. Amplification and sequencing of LTNP4 viral sequences
RNA from cultured virus as well as patient plasma virus was isolated by lysing
virions with lysis buffer (Tris-HCl/68%guanidine thiocyanate/3%DTT) for 10 minutes at
room temperature. The RNA was precipitated with isopropanol and resuspended in a
Tris buffer. Reverse transcription was carried out using the ThermoScript RT-PCR
System from Gibco-BRL (Grand Island , NY) according to manufacturers instructions
with random hexamers.
2f!l of the RT reaction containing the PCR-amplified cDNA was then used in a
PCR reaction using Tag polymerase (Gibco) with two HIV - 1 vif-specific primers,
IS5' GT ACAAA TGGCAGT A TTCA TCCAC3' and IA5' TT A TT A TGGCTTCCACTC
CTGCCC3' , in a 100f!l reaction. Amplification was achieved using 25 cycles each
consisting of 94 for 1 minute for denaturation
, 50 for 1.5 minutes for annealing, 72 for
2 minutes for extension , and a final extension step of 72 for 10 minutes in a Perkin
Elmer 9700 Thermal Cycler. A nested PCR reaction was then performed under similar
PCR parameters using 5f!l PCR product from the previous reaction with the vif specific
primers Vif-F s' GGTGAAGGGGCAGTAGTAATACAA3' and Vif-
RS' GTGTCCA TTCA TTGT A TGGCTCCC
To determine the sequence of proviral DNA in patient cells
, whole celllysates of
patient CD4+ T cells were prepared using Tris-HCl (pH7. 3), 1 %Triton X- lOO , 7.5mM
MgCh, 0. 01 % Proteinase K
, and 0. % sodium azide for 30 minutes at 60 C followed by
30 minutes at 100oC. 5",1 of whole cell lysate was used 
as the template in a nested PCR
reaction using the same Vif-
IS/IA and FIR primers , polymerase , and cycling protocol
described above.
The final PCR product was purified using the QIAquick PCR Purification kit
from Qiagen (Valencia
, CA) following the manufacturers protocol. Sequencing was
performed using the following primers
, Vif-IIF 5'GTTCAGAAGTACACATCCC
and Vif-IIR GTGGGATGTGTACTTCTGAAC
, in a Big Dye Terminator
sequencing reaction. All sequencing was performed on an ABI 377 XL 
Prism at the
UMass Center for AIDS Research Molecular Biology Core Facility. Sequences were
analyzed using the Sequencher software package.
Sequences presented in Chapter III were aligned against the consensus clade B vif
sequence from the Los Alamos National Laboratory (LANL) database. The frequency of
mutations in the population was also derived from the sequences deposited in the LANL
database.
F. Plasmid construction and mutagenesis
To generate isogenic clones of NL4. 3 that differed only at the KKRK motif in
Vif, site directed PCR mutagenesis was used. Site directed PCR mutagenesis was
achieved using the full length HIV- l plasmid NL4. 3 as a template in the Stratagene
QuikChange Site-Directed Mutagenesis kit (Stratagene
, La Jolla , CA). The NL4.3
plasmid template was propagated in Stbl II competent cells from Invitrogen (Carlsbad
CA) to ensure methylation of the template. Methylated template NL4.3 was used with
the following gel purified primers
, VifKI TCCATAGAATGGAAGAAAAGAAAA
ATAGCACACAA ' and Vif- K25' TTGTGTGCTATATTTTCTTTTCTTCCATTCTAT
GGA ' to generate substitution mutations of arginine to lysine
, lysine to arginine , and
arginine to lysine as indicated by the underlined nucleotides. 20 amplification cycles of
for 1 minute , 45 for 1 minute , and 68 for 35 minutes followed by a final extension
of 68 for 7 minutes were performed. Following amplification
, the PCR product was
subjected to 3 hours of digestion by DpnI at 37 C to degrade the methylated input
. template. 50 to 200 ng of the mutagenized plasmid was then used to transform INVaF'
competent cells from Invitrogen (Carlsbad
, CA). Clones were selected and the sequence
confirmed by full length sequencing of the plasmid.
The same site directed mutagenesis approach was used to generate the NL4.3/I
plasmid. Here , the primers used were VIF-HF 5'CATATCTATTCATCAAGGAAAGC
TAAGGACTGGATATATAGACATC ' and VIF- HR 5' GATGTCTATATATCCA
GTCCTT AGCTTTCCTTGA TGAA T AGA T A TG
For the initial subcellular localization studies in Chapter III
, the pDsRedl-
fusion vector from Clontech (Palo Alto
, CA) was used to generate in-frame , N-terminal
DsRed- Vif fusion proteins. Wild type and mutant vif sequences were amplified from the
NL4. 3 templates using Vif-Nhe 5'GGCTAGCTTATGGAAAACAGATGG3' and Vif-
Eco 5' CGGAATT CGCTGTCCATTCAT
' in a rOO l PCR reaction using 25 cycles of
for 1 minute , 48 for 1 minute , 72 for 3 minutes , and a final extension of 72 for 10
minutes. PCR products were digested with EcoRI and NheI and ligated into the
EcoRIIheI digested DsRed vector using T4 DNA ligase from New England Biolabs
... . --_
t'-
(Beverly, MA). The pCMV/myc/nuc/GFP plasmid from Invitrogen (Carlsbad , CA) was
used as a control for nuclear localization,
The HL8 Vif shuttling construct used in Chapter V was constructed by amplifying
and cloning the DsRed- WT vif fusion gene into a vector that contained a linker region.
The stop codon of DsRed was removed and it was inserted N- terminal to a linker region
with a stop codon in its C- terminus. By inserting a linker region , the molecular weight of
the DsRed- WT Vif construct was elevated above the cutoff for passive nuclear diffusion.
A GFP-tagged Rev protein (kindly provided by Dr. Maria Zapp, UMass Medical School)
was included as a nucleocytoplasmic shuttling protein control.
The GFP-tagged Apobec3G fusion construct used in Chapters IV and V was
generated by amplifying the pcDNA-Apobec3G plasmid (kindly provided by Dr. Michael
Malim , King s College) with the primers GFP-HindII 5' CCC AAG CTT GGG ATG
AAG CCT CAC TTC3' and GFP- EcoRI 5' GCG GAA TTC CTG TCA GTT TIC CTG
3' and cloned into the eGFP- C3 vector (Clontech , Palo Alto, CA), An empty vector
(kindly provided by Dr. Maria Zapp, UMass Medical School) was also included in those
studies to insure that equal amounts of total DNA were transfected in each co-
transfection experiment.
For rVif constructs , vif was amplified from either the NL4.3/KKRK or NL4.3/WT
plasmid using the primers pHAT-EcoRI 5' GGA ATT CCC TAC TGT CCA TTC ATT 3'
and pHAT-BamHI 5' GGG ATC CTT ATG GAA AAC AGA TGG 3' and cloned into the
pHA Tll vector (Clontech , Palo Alto, CA). For the rApo construct , apobec3G was
amplified from the pcDNA-Apobec3G plasmid with the primers pHAT-KpnI 5' CGG
GGT Ace CCG ATG AAG CCT CAC TTC 3' and pHAT- EcoRI 5' GCG GAA TTC
CTG TCA GTT TTC CTG 3'
All constructs were confirmed by amplification and sequencing as above and
Western blot or immunofluorescence microscopy for expression.
G. Production of viral stocks
Virus stocks for NL4. 3/WT, NL4. 3/KKRK , or NL4.3/IF were generated by
transfection of permissive or non-permissive cell lines. Non-permissive HUT78, H9, or
CEM or permissive CEM-SS cells were seeded 24 hours prior to transfection and the
SuperFect Transfection Reagent kit from QIAgen (Valencia, CA) was used. Hela cells
were seeded 24 hours prior to transfection with the PolyFect Transfection Reagent kit
from QIAgen. Culture supernatant was harvested 72 hours post-transfection and assayed
for production of virus by a p24 ELISA detection assay. For the aggresome studies
presented in Chapter V , CEM or CEM-SS cells were infected with 100ng p24 for two
days prior to being washed three times and split into four fractions. One group for each
cell line received 1 O lM lactacystin , lO""M nocodazole , or lO""M Scriptaid for 18 hours.
H. Infectivity assays
For the spreading infection assay presented in Chapter II, H9 or CEM-SS cells
(2x 1 0 ) were infected with 5ng of p24 with 8""g/ml DEAE-dextran for 3 hours followed
by five washes in media. Replication was followed for two weeks by culture supernatant
sampling and p24 ELISA detection assay. The viral rescue assay presented in Chapter 
utilized a co-culture of transfected HUT78 cells with HUT78 or HUT78xVif cell lines.
2x 10 parental or Vif complementing HUT78 cells were washed once in RPMI/lO% FBS
and then added to 2x 1 0 transfected HUT78 cells in a 24 well plate. All cell cultures
were incubated at 37 C in a 5% CO humidified incubator. Culture supernatants were
assayed for virus production p24 ELISA detection assays every 3 to 4 days post-co-
culture. For the single cycle infectivity assays presented in Chapter II and V , GHOST-
X4 cells were infected overnight with culture supernatant containing virus normalized to
100ng of p24, or for 3 hours in the presence of 8""glml DEAE-dextran followed by three
media washes. Cultures were washed and assayed by FACS analysis for %GFP+ cells
three days post- infection.
I. Subcellular localization ofVif and Apobec3G
The localization studies shown in Chapter II utilized DsRed tagged WT or
KKRK Vif constructs. For these experiments , MAGI cells were seeded to subconfluency
on coverslips in a six well plate and allowed to adhere at 37 C for 12 hours prior 
transfection. 20ug of the plasmid construct was ethanol precipitated and resuspended in
450/ll sterile water and 50/l1 2M CaCho The DNA mixture was then added dropwise to
500/ll 2xHBS pH 7.08 while vortexing and incubated for 20 minutes on ice. The mixture
was then added dropwise to the cells and incubated at 37 C for 16 hours. The cells were
washed three times with PBS and twice with media. 5ml of DMEM/lO% FBS
supplemented with 200/lg/ml G418, and 100/lglml Hygromycin B was added back.
Forty-eight hours post- transfection , the coverslips were fixed in 1 % formaldehyde
for 15 minutes at room temperature and washed 6x 30s in PBS/1 %BSAlO. % Tween.
Ice-cold methanol was added for 15 minutes followed by a 6x 30s wash as above. 
DAPI
stain was applied for 1 minute and then the coverslip was washed 3xin sterile water. 
The
coverslip was then mounted on a slide using the Pro-long Antifade Kit from Molecular
Probes (Eugene, OR). Image acquisition was performed at the UMass Digital Imaging
Core Facility on an Olympus IX 70 inverted microscope equipped with a Physik L 
VPZT
piezo-electric focus drive. A series of planes were acquired at 0. 211 intervals using a
PlanoApo lOOx oil immersion lens with a DAPI
, FITC , or TRITC filter. All images were
stacked and deconvolved using the Universal Imaging MetaMorph 
software package.
Colocalization values were determined using the colocalization feature in MetaMorph.
For the colocalization of NL4. 3/WT and NL4. 3/KKRK Vif with GFP-Apobec3G
shown in Chapter IV, Hela cells were grown on coverslips and transfected at a I: 
1 ratio
of NL4.3/KKRK or NL4. 3/WT and GFP-Apobec3G. 48-60h post- transfection
coverslips were washed and fixed in - C methanol. Following a 30min block in
PBSA T (PBS/1 %BSNO. %Tween-20) at 37 , covers lips were stained with the 319
mAb against Vif, obtained through the AIDS Research and Reference Reagent Program
Division of AIDS , NIAID, NIH: HIV- l VifMonoclonal (#319) from Dr. Michael H.
Malim , and a Cy-3 conjugated anti-mouse Ig whole molecule (Sigma
, St. Louis , MO).
DAPI stain was applied and the coverslips were washed and mounted using Pro-
Long
Antifade (Molecular Probes
, Eugene, OR).
For the subcellular localization studies of NL4.3/WT and NL4. 3/KKRK presented
in Chapter IV, GHOST-X4 cells were grown on coverslips and infected with lOOng p24
NL4. 3/KKRK or NL4.3/WT plus 8ug/ml DEAE-dextran for 48-60h. Following
infection , coverslips were fixed and stained for Vif as above.
;: -
HUT78 cells were infected with 50ng p24 NL4. 3/KKRK or NL4.3/W plus
8ug/ml DEAE-dextran for three hours. Coverslips were washed three times in media and
incubated in RPMIIlO%FBS. Three days post- infection , HUT78 cells were spotted onto
coverslips and spun down at 2400xg for 15min. Coverslips were washed three times 
with
PBS , fixed in methanol , and washed three times in PBS
, all steps were performed in a
six-well plate on ice. Coverslips were then blocked with PBSAT at 37
, two times ten
minutes , and stained for Vif and DAPI as above.
Differential lysis of Hela-Apo cells transfected with NL4. 3/W or NL4. 3/KKRK
was achieved by first treating the cells with permeabilization buffer (29mM Hepes, pH
7.4 , 1 lOmM KOAc , 2mM MgOAc , ImM EGTA , 200mM NaCl , 0.01 % digitonin) for
seven minutes on ice. This detergent system wil allow lysis of the plasma membrane
while leaving the nuclear membrane intact. The lysates were centrifuged at 3000xg for
five minutes at 4 C to pellet the nuclear fraction. The post-nuclear supernatant was
removed and the pelleted fraction was washed twice with permeabilization buffer. After
the second wash , the nuclear fraction was lysed with a 1 %NP-40 buffer for 30 minutes on
ice. Both the post-nuclear and nuclear fractions were immunoprecipitated with a- Vif
(kindly provided by Dr. Klaus Strebel) and resolved on a 12% SDS-PAGE gel and
transferred to PVDF membrane. The membranes were probed with a- Vif (kindly
provided by Dr. Dana Gabuzda) or a-tubulin mAb (Sigma, St. Louis , MO) followed by a
HRP-conjugated anti-mouse secondary. The Enhanced Chemiluminescence (ECL) Kit
(Pierce , Rockford , IL) was used to detect signal.
The aggresome studies presented in Chapter V were performed by growing Hela
cells on covers lips and co-transfecting with NL4. 3/WT and GFP-Apobec3G at a 1: 1 ratio
r7?
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or with GFP-Apobec3G or DsRed- Vif alone. Or
, Hela-Apo cells were transfected with
NL4.3/W. Coverslips were processed as above
, except for HDAC6 , which was
incubated overnight at 4 C in primary antibody. Staining for ubiquitin was done with a
a-ubiquitin polyclonal Ab
, Vif was detected using a poJyclonal antibody generously
supplied by Klaus Strebel or the 319mAb
, HDAC6 detection was achieved with a a-
HDAC6 mAb , and tubulin was detected with a a- tubulin mAb (unless noted
, all
antibodies are from Sigma, St. Louis
, MO). Secondary antibodies used were Cy-
conjugated a-mouse IgG
, Cy-3 conjugated a-rabbit IgG
, or FITC conjugated a-mouse
IgG (Sigma , St. Louis , MO). Leptomycin treatment was done with 5ng/ml leptomycin
for 2.5 hours. Nocodazole treatment utilized lO/lM 
nocodazole for 3 hours.
Image acquisition was performed at the UMass Digital Imaging Core Facility on an
Olympus IX 70 inverted microscope using a PlanoApo 
lOOx oil immersion lens with a
DAPI, FITC, or TRITC filter for fluorescence images and a phase filter for phase contrast
images. All images were processed using the Universal Imaging 
MetaMorph software
package. Colocalization values were determined using the colocalization feature in
MetaMorph.
J. FACS analysis
The GHOST infection assay, shown in Chapter 
II was done by using FACS to
determine the number of GFP+ cells in each culture. Infected GHOST -
X4 cells were
collected , washed twice with PBS
, resuspended in 250 to 300ul PBS
, and analyzed by
one-color flow cytometry using FACSort and Cell Quest software (BD Biosciences
, San
Diego , CA). Un infected GHOST-X4 cells were included as a control for setting the gate
to determine GFP+ cells and for background fluorescence levels. Relative infectivities
were established by subtraction of background fluorescence followed by setting the
NL4. 3/WT value at 1.
The GFP degradation assay presented in Chapter IV utilized FACS to follow the
GFP signal in cultures over a period of six days. GFP vector or GFP-Apobec3G were co-
transfected at a 1: 1 ratio with NL4. 3/KKRK, NL4.3/WT , or empty vector in Hela cells.
Cells were collected and washed twice with PBS, resuspended in 250 to 300ul PBS, and
analyzed by one-color flow cytometry using F ACSort and Cell Quest software (BD
Biosciences , San Diego, CA). Untransfected Hela cells were included as a control for
setting the gate to determine GFP+ cells and for background fluorescence levels. Cells
were analyzed on days 2 , 3 , 4 , and 6 post-transfection.
K. Virion incorporation of Apobec3G
Virion incorporation of Apobec3G was assayed by collecting virions by
ultracentrifugation and lysing the virion pellet in 1 %NP-40 lysis buffer overnight at 4
Proteins were concentrated with a Centricon YM- lO centrifugal filter unit. Equal
amounts of p24 were added to a 12% SDS-PAGE gel. Blots were probed with a
monoclonal antibody against Apobec3G (ImmunoDiagnostics , Inc , Woburn , MA) and a
monoclonal antibody against p24 obtained through the AIDS Research and Reference
Reagent Program , Division of AIDS , NIAID , NIH: Hybridoma 183 (Clone HI2-5C) from
Dr. Bruce Chesebro. Enhanced Chemiluminescence was used to detect signal (Pierce,
Rockford , IL). Packaging ratios were determined by using the Kodak ID 3.0 software.
L. Expression of rVif and rApo
BL21 Star (DE3) cells (Invitrogen , Carlsbad, CA) were transformed with pHA T-
KKRK , pHAT- , or pHAT-Apobec3G expression vectors. Transformed cultures were
selected and a 20ml overnight culture was setup in LB broth plus ampicillin in a 37
shaking incubator. This culture was used to seed lL of LB broth supplemented with
glucose (I Og/L) for 2-3h. IPTG (Sigma , St. Louis, MO) was added to the 1 L culture to a
final concentration of ImM. Following a 5 hour incubation at 37 , cells were harvested
by centrifugation at 2000-3000g at 4 C for 15-20 minutes at 4 C. Cells were
resuspended in extraction buffer (50mM Na2HP04
, 300mM NaCl pH7.0), treated with
75mg/mllysozyme (Sigma, St. Louis , MO) for 25min at room temperature , and then
lysed by sonication. The cell supernatant was clarified by centrifugation at 12 000g for
20 minutes at 4 C before being applied to a TALON resin (Clontech
, Palo Alto, CA)
M. Immobilized pull-down for Vif-Apobec3G interaction and aggresome markers
Interaction of rVif or rApo with GFP-Apobec3G , Hsp70, HDAC6 , or vimentin
was determined by incubating celllysates from unifected HUT78, infected HUT78
, or
GFP-Apobec3G transfected Hela with immobilized rVif or rApo. For GFP-Apobec3G
binding, purification , and recovery, eluates were concentrated with the Centricon YM-
centrifugal filer unit (Millipore
, Bedford , MA) and a Bradford assay was done to
determine protein concentration. For all other pull-down assays , a Bradford assay was
performed on all eluates. Following the Bradford assay, equal amounts of protein from
the eluates were resolved on a 10% or 12% SDS-PAGE gel followed by transfer to a
PVDF membrane. The membranes were probed with the mAb 319 against HIV- I Vif
and a monoclonal antibody against Apobec3G (ImmunoDiagnostics, Inc , Wobum , MA).
Blots were also probed with antibodies against Apobec3G, Hsp70 , HDAC6 , or vimentin
(Sigma, St. Louis, MO).
CHAPTER III
NUCLEAR LOCALIZATION OF HIV - 1 VIP ISOLA TED FROM A LONG-TERM
ASYMPTOMA TIC INDIVIDUAL AND POTENTIAL ROLE IN VIRUS
A TTENUA TION
A. Introduction
As one of the six accessory genes of HIV -
, Vif performs a critical function
necessary for production of infectious virions in primary blood lymphocytes and
macrophages as well as certain T cell lines, termed non-permissive (73, 80, 81 294-296
355). Permissive cell lines such as SupTl do not require Vif for production of infectious
virions. HIV - 1 carrying nonfunctional Vif is defective for completion of reverse
transcription in non-permissive cells (319 , 356-359). Heterokaryon experiments revealed
that Vif is necessary to neutralize an inhibitory cellular factor recently identified as
CEM15 or Apobec3G, a cellular cytidine deaminase expressed only in non-permissive
cells (297 , 298 , 360).
Vif prevents the incorporation of Apobec3G into virions by inducing the
degradation of Apobec3G via the proteasome pathway (329
, 332 , 333 , 36l). In the
absence of Vif, Apobec3G is packaged in the virion , and upon infection the encapsulated
Apobec3G edits the single-stranded DNA during reverse transcription by inducing
deoxycytidine to deoxyuridine deamination. These G to A hypermutations in the viral
genome lead to activation of DNA repair pathways that result in premature degradation
of the newly synthesized reverse transcripts (120 308). Recent reports implicate an
additional member of the Apobec3 family as an antiretroviral factor. It has been shown
that Apobec3F is also expressed in non-permissive cells where it is able to
heterodimerize with Apobec3G, package into the virion , and induce degradation of the
nascent viral reverse transcripts by deamination. As with Apobec3G, Vif suppresses the
antiviral effect of Apobec3F and prevents its virion incorporation (302, 304).
Since Viffunctionsby interacting with Apobec3G in the cytoplasm , it's
localization there is critical. Vif is localized in a diffuse pattern throughout the cytoplasm
(345), with a fraction that may be associated with cytoplasmic side of membranes (346,
349 350), co- localized with Gag (348-350, 362-364), or in association with the
intermediate filament vimentin (351 , 365).
Since Vif is necessary for production of infectious virions in vivo, it has often
been studied in the context of patient isolates that exhibit diminished replicative capacity.
Such viruses are typically isolated from a group of infected , but asymptomatic
individuals known as long-term non-progressors (LTNP); individuals who maintain low
viral loads and stable CD4+ T cell counts in the absence of antiretroviral therapy. Some
viruses isolated from L TNP have been found to harbor mutations in vif that may
compromise the replicative and/or cytopathic abilities of HIV - 1 (82 , 83, 366, 367).
These Vif mutant viruses are useful tools in investigating the functions of Vif. In this
study, a viral isolate from a long-term non-progressor containing vif mutations was used
to study Vif trafficking and how this affects Vif function.
- .
B. LTNP4 isolate shows Vif-enhanced growth phenotype.
One individual (L TNP4) in the New England Area Hemophilia Cohort has
displayed a particularly remarkable course of infection for more than twenty years. The
clinical , virological and immunological characteristics of L TNP4 were first described in
detail in 1994 (368), emphasizing the inability to isolate virus and potent virus-specific
cellular immune responses. Ten years later
, this individual shows no evidence of mv-
related disease. On the majority of study visits
, LTNP4 has had plasma viral RNA levels
that were undetectable at a threshold of 50 copies/ml. On occasion
, viremia was detected
at levels -( 400c/ml , and had a single peak value of 1 404c/ml (Figure 3. 1A). LTNP4 has
maintained CD4+ T cell counts that range between 500 and 1500 cells/,ul with an average
of 1229 cells//-l (Figure 3. 1B). While receiving interferon therapy for hepatitis C virus in
late 2003 , absolute CD4+ T cell count fell to 432 cells/fll
, but the percentage of CD4+ T
cells remained stable at 50% with a CD4+/CD8+ ratio;: 2 , and the plasma viral RNA level
was -( 50c/ml. Virus-specific immune responses remain vigorous with cytolytic CD8+ T
cell responses to Gag, Pol , and Env , and significant CD4+ and CD8+ proliferation to viral
antigens.
Exhaustive attempts to culture the L TNP4 virus using a variety of co-culture
techniques proved unsuccessful until enhanced techniques were developed that involved
selection of donor cells with high levels of CD4 and CCR5 expression after PHA
activation (369). Early culture attempts employed several types of donor cells as well as
Tat and Rev-complementing T -cell lines (368-370). Virus replication in T 
-cell lines was
only observed when Vif-complementing cell lines were co-cultured with L TNP4 PBMC
and RNA PCR was used to detect virus in culture supernatant (Figure 3.2A). While the
virus did not replicate to detectable levels in parental T -cell lines
, WT Vif provided in
trans was sufficient to rescue the virus. Thus , virus from L TNP4 exhibited a Vif-mutant
replication phenotype.
To exclude the possibility that the ability to grow the L TNP4 virus was due to a
non-specific cellular effect as a result of Vif over-expression
, another slow-growing viral
isolate from a different long-term non-progressor, LTNP6 , that has been shown to have
unique , difficult to revert polymorphisms, in regions other than Vif, was tested for the
ability to grow in the parental and Vif-complementing cell lines (367). Growth of this
virus was observed in both cell lines at low levels
, providing evidence that growth of the
L TNP4 isolate was enhanced by Vif expression. In these experiments , the low level
growth of the L TNP viruses was attributed to the fact that they are kno\vn to use CCR5 as
a co-receptor , and the T cell lines primarily express the CXCR4 co-receptor. This growth
phenotype of L TNP4 virus was consistently observed at multiple time points. Based on
this observation , the vif gene of the L TNP4 isolate was further characterized
genotypically and phenotypically to explore the role of Vif in viral replication.
C. LTNP4 isolate contains a unique motif in the vif gene.
Sequence analysis of the vif gene of the L TNP4 isolate revealed a complete open
reading frame with no frameshift mutations or early termination codons. A number of
point mutations resulting in amino acid substitutions were observed in comparison to the
consensus clade B Vif sequence (Figure 3.2B). Substitution mutations are classified by
their frequency of occurrence in the HIV database with mutations of the lowest frequency
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Figure 3. 1: Viral loads and CD4+ T cell counts for L TNP4. (A) L TNP4 plasma viral
loads were determined by PCR using the Roche Amplicor HIV 1 detection kit. Prior to
1997 , the limit of detection for the assay was .c400copies/ml. The sensitivity of the assay
was then improved to .c50 copies/ml. (B) L TNP4 CD4 cell counts were determined by
flow cytometry (FACScan , Becton Dickinson). The average cell count gives a value of
1229 cells/!ll as represented by the trendline.
representing the most interesting to explore in terms of structure or function while
common mutations are seen as potential byproducts of high error rates of the reverse
transcriptase enzyme or as escape mutants that confer a fitness advantage to the virus. A
motif not previously reported in Vif was observed at amino acid positions 90 to 93 where
the clade B sequence of RKRR was replaced with KKRK , a motif that commonly
functions as a nuclear localization signal (NLS) in many viral and cellular systems (371).
This unique substitution was observed in the majority of viral sequences obtained from
LTNP4 plasma, PBMC DNA, and cultured virus at multiple timepoints in 1991 , 1997
2000 2001 , and 2003 (Figure 3.2B).
D. Nuclear localization of KKRK Vif
Based on the observation that KKRK is a nuclear localization sequence , we
hypothesized that Vif would be localized aberrantly to the nucleus, thereby rendering Vif
non-functional. WT Vif is found primarily in the cytoplasm where it plays a critical role
in the production of infectious virions (81 , 295, 348 , 355 , 359, 372). To determine the
subcellular localization of the KKRK Vif, N- terminal DsRed fusion proteins were made
using the WT and KKRK Vif sequences. As a control for nuclear localization , a GFP-
tagged protein harboring the myc NLS of DPKKRKV was included. These constructs
were used to transfect MAGI cells and localization of the fluorescent fusion proteins was
determined by fluorescence microscopy. A Z-series of images was acquired at 0.2!-m
intervals for the DAPI stain and the DsRed or GFP fluorescence. Following image
processing on MetaMorph software, the images were overlaid to determine subcellular
localization. The subcellular localization patterns of the DsRed protein alone , the KKRK
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Figure 3.2: L TNP4 exhibits a Vif enhanced growth phenotype and unique mutations in
Vif. (A) 2x 1 0 IL-2 stimulated , CD8-depleted PBMC of L TNP4 were co-cultured with
2x 1 0 parental or Vif-complementing H9 or HUT78 cells for 21 days. Culture
supernatant was sampled for virus production by viral RNA quantification at days 7 , 14
and 21. (B) LTNP4 Vif sequence was determined by RT-PCR of culture supernatant or
plasma virus for replicating viral species or by direct PCR of celllysates for integrated
virus. The consensus clade B strain was used for alignment. Sequences that occur at low
frequencies in the Los Alamos National Laboratory HIV- l database are highlighted and
underlined, sequences unique to the database are highlighted and italicized. Positions 90
to 93 represent a nuclear localization sequence , the underlined Ser95 and Thr96 residues
designate potential cAmp-dependent protein kinase A or casein kinase II phosphorylation
sites, respectively.
and WT Vif fusion proteins, and GFP nuclear protein are shown (Figure 3A-L). DAPI
staining was used to specifically identify the nucleus (Figure 3.3A-D). The vector
construct revealed DsRed fluorescence throughout the cytoplasm (Figure 3. 3E).
Overlaying the DAPI and DsRed fluorescence images showed dispersed DsRed
fluorescence throughout the cytoplasm (Figure 3.3I). The DsRed-WT Vif construct
exhibited a similar pattern of dispersed fluorescence throughout the cytoplasm as well as
the perinuclear compartment (Figure 3. , F, and J). However, the DsRed-KKRK Vif
construct demonstrated a dramatically different pattern. DsRed images revealed a
punctate DsRed fluorescence apparently in the nuclear compartment (Figure 3.3G).
Overlaying the DsRed image with the DAPI image confirms that the localization of
DsRed-KKRK Vif is predominantly nuclear (Figure 3.3K). This fluorescence pattern was
observed only in DsRed-KKRK Vif transfected cells. The GFP-tagged nuclear control
(Figure 3. 3D, H, and L) exhibits an exclusively nuclear stain.
To confirm the observation that DsRed-KKRK Vif appeared to localize
predominantly to the nucleus, the localization for each construct was quantitatively
determined using the colocalization feature of the MetaMorph Software package. For
this analysis, the amount of colocalization between the fluorescent signal and nuclear
DAPI stain was calculated for each cell completely in the field. The DsRed vector gave
the expected pattern with exclusive cytoplasmic localization. The GFP-myc nuclear
control protein showed a distinct nuclear distribution with 96% of the signal being
detected in the nucleus. DsRed- WT Vif also exhibited the expected distribution pattern
of predominantly cytoplasmic. The distribution ratio was 66% cytoplasmic to 34%
nuclear. However, this ratio was inverted for the DsRed-KKRK construct which
exhibited a 27% cytoplasmic to 73% nuclear distribution. The ratios presented here are
consistent with a series of images analyzed for each construct. While the localization of
DsRed-KKRK Vif is not exclusively nuclear, it does demonstrate an aberrant localization
when compared to the DsRed- WT Vif. This finding supports the hypothesis that Vif is
localized to the nucleus in the presence of the KKRK substitutions. Since the KKRK
mutation is unique and coul.d have functional consequences due to aberrant localization
of Vif, experiments were undertaken to investigate possible effects on viral replication.
E. Presence of KKRK motif reduces virus infectivity.
Following the genotypic analysis of the L TNP4 viral species and subsequent
analysis of the impact of the KKRK mutation on Vif localization , the effect of the KKRK
mutation on viral infectivity was investigated. Two experimental approaches were
employed to assess the contribution of KKRK to viral infectivity. The first approach
involved using a co-culture system similar to the one used in the initial isolation of the
L TNP4 virus. Although not a direct assay of Vif function , this experiment replicated the
conditions under which the L TNP4 KKRK Vif mutation was first detected and was
performed to confirm the original viral growth data shown in Figure 3.2A. The second
set of experiments involves the traditional spreading infection assay and a single-cycle
infectivity assay using the GHOST-X4 indicator system to directly assess the replication
phenotype of a KKRK Vif virus.
Mutagenesis was performed using the X4 tropic, cytopathic HIV - 1 clone NL4.
to determine the contribution of the KKRK mutation on the replicative capacity of the
virus. Isogenic NL4.3 clones were generated that differed only with respect to the Vif
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Figure 3. 3: Subcellular localization of KKRK and WT Vif fusion proteins. DsRed
fusion proteins were made with NL4.3/WT Vif or with NL4. 3/KKRK Vif and used to
transfect MAGI cells to determine localization of WT versus KKRK Vif. DsRed vector
and a GFP-nuclear protein were included as controls A Z series of images was acquired
at 0.2um intervals and images were processed using the MetaMorph software.
Fluorescence signals for DsRed vector (E), DsRed-WT Vif (F), DsRed-KKRK Vif (G),
and GFP-nuclear (H) are shown. DAPI staining of the nucleus is shown in Panels A-
To qualitatively assess subcellular localization , overlays of DAPI and the fluorescence
signals were done for DsRed vector (I), DsRed-WT Vif (J), DsRed-KKRK Vif (K), and
GFP-nuclear (L). Subcellular localization was quantified by determining the percent
overlap of the fluorescence signal with the DAPI nuclear stain and presented as nuclear
or cytoplasmic.
KKRK motif. Analysis of culture supernatants from transfected non-permissive HUT78
cells and permissive HeLa cells revealed that the NL4. 3/KKRK clone produced virus
upon transfection to equivalent levels as wild- type NL4. 3 transfections 48 hour post-
transfection.
The basis of the co-culture experiment is that non-permissive cells harboring a
f' Vif virus can effectively transmit virus via the cell-cell transmission route. Although
the producer cell is non-permissive , i.e. expresses Apobec3G, and cell-free virus
produced from these cells is non- infectious (372), it has been previously shown that f' Vif
virus can be efficiently transmitted to a permissive target cell by co-culture (347, 373).
Once the virus enters the permissive cell and is successfully integrated into the host
genome , all virions produced wil be infectious since there is no Apobec3G present for
packaging into the virion. In our system , the exogenously supplied wild- type Vif in the
HUT78 Vif-complementing cell line renders that cell permissive. Therefore, a Vif
rescued virus produced by the HUT78 Vif-complementing cells can initiate a spreading
infection driven by production of infectious, cell-free virions.
If NL4.3/KKRK is a Vif-mutant virus , co-culture of transfected HUT78 cells with
parental HUT78 cells should not enhance viral replication. However, transfected HUT78
cells co-cultured with HUT78xVif cells should show enhanced replication levels due to
the permissive environment in the target HUT78xVif cell. HUT78 cells that were
transfected with NL4.3/KKRK and co-cultured with parental HUT78 cells gave peak p24
levels that were consistently lower than NL4. 3/WT transfected HUT78 cells co-cultured
with parental HUT78 cells. However, when NL4.3/KKRK transfected HUT78 cells were
co-cultured with the HUT78xVif cells, the amount of p24 in the supernatant was elevated
to a level comparable to NL4.3/WT. When peak p24 values observed in the Vif-
complementing HUT78 co-cultures were normalized based on peak p24 levels in the
parental HUT78 co-cultures , the NL4.3/WT virus gained no replication advantage from
the presence of exogenous Vif. However, NL4.3/KKRK exhibited an enhanced
replication phenotype similar to that of the primary isolate from LTNP4 during co-culture
with T cell lines expressing Vif (Figure 3.4A).
To determine if the NL4. 3/KKRK virus exhibits a Vif-mutant phenotype (i.e. less
infectious when produced from non-permissive cells, but infectious when produced from
permissive cells), viral stocks were produced from both non-permissive H9 or HUT78
and permissive HeLa cells and used in spreading infection and single-cycle infectivity
assays.
Initial experiments indicated that the NL4.3/KKRK virus was less infectious
when derived from or passaged on non-permissive cells. To confirm this, a spreading
infection assay was performed using virus from a non-permissive or permissive source to
infect either the non-permissive H9 or permissive CEM-SS cell line. Replication was
followed for two weeks by the p24 ELISA culture supernatant assay. When NL4.3/WT
virus is derived from either a non-permissive or permissive source , it is infectious when
passaged on non-permissive and permissive target cells (Figure 3.4B and 3.4C).
NL4. 3/KKRK from permissive cells is infectious when passaged on permissive target
cells (Figure 3.4C). On the other hand, the NL4.3/KKRK virus produced from non-
permissive cells exhibits a delayed and significantly lower replicative capacity when used
4321q to infect a non-permissive target. Here, spreading infection is delayed for one
week and detected at a tenfold lower level compared to NL4.3/WT (Figure 3.4B).
The single-cycle GHOST assay was also used to investigate differences in
infectivity between NL4. 3/WT and NL4. 3/KKRK derived from non-pennissive as well as
permissive sources. Virus was normalized to 100ng of p24 and used to infect GHOST-
X4 cells for 24 hours. GHOST-X4 cells express both the CD4 receptor and the CXCR4
co-receptor that allow HIV- l infection. Additionally, these cells harbor a reporter
plasmid that expresses the GFP protein under control of the HIV - I L TR. Upon
successful infection of these cells by HIV - , expression of HIV - 1 Tat protein leads to
activation of the LTR and expression of GFP. When viruses derived from permissive
HeLa cells were used for infection , the NL4. 3/KKRK virus was equally as infectious as
the WT virus, as expected (Figure 3.4D). However, when viral stocks produced by the
non-permissive HUT78 cells were used, the relative infectivity was significantly
impaired compared to the NL4.3/W (unpaired t-test, p -: 0.05). To confirm the
observations that both the L TNP and NL4.3/KKRK constructs are capable of infection by
cell-cell spread , transfected HUT78 cells were co-cultured with GHOST-X4 cells and
assayed for relative infectivity as above. Again, the NL4. 3/KKRK virus was equally as
infectious as the NL4. 3/WT virus when cell-cell transmission , rather than cell-free virus
was utilized.
These experiments demonstrate a Vif-dependent effect where the "permissivity
of a cell line determines the infectivity of progeny virus. Taken together, these results
demonstrate that the NL4.3/KKRK virus exhibits a Vif-mutant phenotype and is
significantly less infectious than the NL4.3/W virus.
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Figure 3.4. Infectivity of NL4.3/WT versus NL4.3/KKRK viruses. (A) HUT78 cells
were transfected with NL4.3/WT or NL4.3/KKRK and co-cultured with HUT78 parental
or Vif-complementing cells. Virus replication was followed by p24 production. Peak
p24 data for the HUT78- Vif cell line cultures were normalized to that of the HUT78
parental culture. Enhanced replication of NL4.3/KKK construct is indicated by a
normalized value greater than one. Data are from two experiments with standard error
shown. (B) Non-permissive H9 (source) cells were transfected with NL4.3/WT or
NL4.3/KKRK. Cell-free virus normalized to 5ng of p24 was used to infect H9 (target)
cells. The accumulation of p24 in culture supernatant was measured using a quantitative
ELISA assay. (C) Permissive HeLa (source) cells were transfected with NL4.3/WT or
NL4. 3/KKRK. Infections of permissive CEM-SS (target) cells were performed and
assayed as in B. (D) NL4.3/WT or NL4.3/KKRK viruses were produced by transfection
of the non-permissive HUT78 cell line , or the permissive HeLa cell line. Viruses were
normalized to lOOng p24 and used to infect GHOST-X4 cells that harbor the GFP protein
under the control of the HIV - 1 L TR. Three days post- infection, GFP positive cells were
enumerated by FACS. Data were normalized to the NL4.3/W values to derive a relative
level of infectivity. Data for the NL4.3/KKRK construct are shown as a percentage of
that observed for the NL4.3/WT construct (* indicates p-c.05).
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F. Additional Vif mutations identifed in LTNP4 virus contribute to attenuation
While the KKRK mutation found in LTNP4 Vif proved to be the most interesting
to explore due to its unique absence in the database, other rare mutations were also found
in the L TNP4 vif gene. Two rare mutations were found in the N-terminus of Vif, an
Isoleucine to Serine substitution at position 31 and a Phenylalanine to Isoleucine
substitution at position 39. Both of these mutations are present at a low frequency in the
LANL database, neither segregates with LTNPs.
Although these mutations are not unique , they are still interesting due to their low
frequency in the database and that they are present in an attenuated virus that shows Vif
enhanced growth. The importance of these additional mutations was determined by
infectivity assays analogous to those used with NL4.3/KKRK. The NL4. 3 template was
mutagenized to generate the plasmid NL4. 3/IF containing the Ile-7Ser and Phe-7Ile
substitutions at positions 31 and 39 (Figure 3.2B). NL4.3/IF was used to produce viral
stocks from permissive Hela cells and non-permissive HUT78 cells. Equal amounts of
p24 were used to infect GHOST-X4 reporter cells and infectivity was measured three
days post- infection as %GFP+ cells. Values were normalized to set NL4.3/WT at a value
of one. When NL4.3/IF virus was produced from permissive Hela cells, it was equally as
infectious as NL4.3/WT. However, when NL4.3/I from non-permissive HUT78 cells
was used , infectivity was reduced to 49% that of NL4.3/WT (Figure 3.5). While this
reduction in infectivity is not as significant as it was with the NL4.3/KKRK construct , it
is stil indicative of an attenuated virus.
When viewed separately, both the KKRK and IF mutations contribute to
attenuated viral phenotypes. In the L TNP4 isolate , the attenuation is severe, with limited
viral replication. This would suggest that both sets of mutations work synergistically to
reduce Vif function in the LTNP4 virus. Future work using a NL4.3 plasmid containing
both the KKRK and IF mutations would be interesting to study to determine if the affect
of both mutations is additive and does render the virus completely non-infectious.
F. Discussion
The studies presented here establish that the presence of a functional NLS in HIV-
1 Vif is sufficient to render the virus significantly less infectious. Previous work has
shown that WT Vif is distributed throughout the cytoplasm. It has also been well
established that Vif is necessary for production of infectious virions. Our working
hypothesis is that the presence of a functional NLS renders Vif non-functional by
retaining it in the nucleus during the viral life cycle, therefore not allowing it to perform
its critical function in the cytoplasm of inducing Apobec3G degradation. Alternatively,
the KKRK mutations may interfere with the direct interaction of Vif with Apobec3G.
This model would account for the observation that the patient isolate, which harbors a
KKRK motif, displays a Vif-mutant replication phenotype.
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Figure 3.5: Comparison of NL4.3/WT and NL4.3/IF infectivity. NL4. 3/WT or NL4. 3/IF
viruses were produced by transfection of the non-permissive HUT78 cell line, or the
permissive HeLa cell line. Viruses were normalized to 1 OOng p24 and used to infect
GHOST-X4 cells. Three days post- infection , the number of GFP positive cells was
determined by FACS. Data were normalized to the NL4. 3/WT values to derive a relative
level of infectivity. Data for the NL4.3/IF construct are shown as a percentage of that
observed for the NL4.3/WT construct.
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The KKRK motif serves as a common NLS for viral and cellular proteins (371).
The KKRK motif reported here is most similar to that of the cellular transcription factor
LEF- 1 and the splice variant of Bcl-2 family member Bfl- , Bfl- 1S. Both contain a NLS
composed of only a KKRK motif with no flanking proline residue (37l , 374). The
prototypical viral KKRK NLS is that of SV40 TAg. The SV40 large T Ag NLS is
dependent on phosphorylation sites flanking the KKK motif (375-379). A sequence
homologous to one of these phosphorylation sites, a consensus site for phosphorylation
by casein kinase 2 (CK2), is present immediately downstream of the KKRK at positions
91-98 (KRKYSTQVD) in Vif. The Thr residue of Vif is phosphorylated by p44/42
mitogen-activated protein kinase (MAPK) in stimulated cell lines (380). Mutation of this
conserved residue significantly reduces the activity of Vif. A sequence homologous to a
second phosphorylation site, a consensus site for phosphorylation by cAmp-dependent
protein kinase A (PKA), critical for the Drosophila morphogen Dorsal NLS (378), is also
found downstream in the Vif sequence at positions 92 to 99 (RKYSTQVDP) (PROSITE
database http://www. expasv.ch/prosite/). It remains to be determined whether
phosphorylation sites flanking the KKRK motif in this unusual Vif protein playa role in
the nuclear localization function of this motif.
The SV40 T Ag utilizes the Importin a/ pathway for nuclear import (381 382).
Upon activation ofT cells (e.g. viral infection), the expression of Importins is
upregulated (383). The presence of critical phosphorylation sites juxtaposing the KKRK
motif in the mutant Vif is consistent with the hypothesis that this sequence functions as a
NLS and relocates the protein to the nucleus, thereby removing it from its site of action.
This may be relevant in view of the observation that T cell activation results in
upregulation of the components of the Importin a/ pathway for nuclear import, the
receptors that recognize this particular motif.
In contrast to the KKRK motif, the NL4. 3 wild- type sequence at these positions,
RKKR , is unable to mediate nuclear translocation. The presence of lysines at the first
and fourth positions, seen in the mutant but not the WT, are the critical energy
determinants for NLS binding to nuclear Importins (384). Preliminary molecular
modeling based on the crystal structure of a KKRK peptide bound to Importin a
suggested that when RKKR was substituted (385), the lysine at position 3 might not
make favorable contacts with the receptor (c. Schiffer
, University of Massachusetts
Medical School , personal communication). Previous reports have examined the potential
of RKKR to function as a nuclear transport inhibitory signal due to the highly basic
nature of the motif. The initial report found that the RKKR motif could function as a
nuclear transport inhibitory signal (NTIS) by associating with Importin a/ and that Vif
could then function by occluding the nuclear import pathway of the cell (386). However,
Stephens et al reported that it is unlikely that the RKKR acts as a NTIS based on the
genetic diversity of this region when different clades and groups are analyzed (387). The
experimental conditions utilized and the IC50 determined with the RKKR peptide make it
unlikely that the RKKR motif can successfully bind Importins under physiologically
relevant conditions. This is supported by the genetic diversity of the region , which makes
it highly unlikely that it plays a functional role by inhibiting nuclear traffic.
Experimental data presented here reveals that the presence of KKRK in place of RKKR is
sufficient for the aberrant localization of Vif from the cytoplasm to the nucleus and the
reduction of replication due to the production of significantly less infectious virions from
non-permissive cells.
The presence of Vif in the cytoplasm of infected cells and its necessary function
in producing infectious virions has been clearly established. Vif interacts with the
cellular protein Apobec3G and induces its degradation via the proteasome pathway (329
332 , 333 , 361). By altering the localization of Vif during the viral life cycle , virus that is
released is less able to spread in culture via cell-free transmission. The ability to
manipulate viral infectivity by altering Vif localization wil be useful for future studies
aimed at elucidating biological functions of Vif, as well as understanding its cellular
trafficking during the viral life cycle. Studies are ongoing to determine the contribution
of the additional Vif substitution mutations along with the KKRK mutation to the
localization and function of Vif and their effects on interactions with Apobec3G.
The remarkable disease course of L TNP4 is probably due to multigenic defects in
the virus including the KKRK mutation in Vif, mutations observed in the env and nef
genes , and perhaps also the I to Sand F to I mutations also present in Vif. While all of
these mutations probably contribute to the severe attenuation of the LTNP4 virus, it is
clear that the KKRK mutation is at least partly responsible for the attenuated growth
phenotype.
Studying unique , naturally occurring mutations , that are present in poorly
replicating primary virus isolates, provides insights into the in vivo function of HIV
proteins. Our analysis of the vif gene of this slow-growing primary isolate confirms the
critical role of Vif localization to the cytoplasm for production of infectious virions. The
consistency and high frequency with which this mutation in Vif was found in the majority
of vif genes in this long-term non-progressor with asymptomatic HIV 1 infection argues
that Vif has an important function in in vivo disease progression. Further characterization
of this Vif mutant may help to elucidate determinants of HIV infectivity and mechanistic
aspects of Vif function.
CHAPTER IV
CYTOPLASMIC LOCALIZATION OF HIV - 1 VIF IS REQUIRED FOR APOBEC3G
DEGRADA TION AND VIRAL REPLICATION
A. Introduction
The function of Vif is to neutralize Apobec3G
, either by direct interaction (334
335) or by directing the degradation of Apobec3G via the proteasome pathway (329-333,
352 361). While many recent studies have focused on the interaction of Vif and
Apobec3G, the proteasomal degradation of Apobec3G
, species specificity of Vif, and
specific Vif mutants, the localization of Vif and Apobec3G during these events has only
begun to be explored. Previous work has established a predominantly cytoplasmic
localization for both proteins (345
, 346, 351-353). Additionally, it has been suggested
that Vif drives the ubiquitylation of Apobec3G via the Cul-SCF5 complex and that this
results in proteasomal degradation of Apobec3G (337
, 338). This pathway functions in
the cytoplasm of cells with the ubiquitylation machinery being in the cytosol and the
proteasome residing in a perinuclear region at or near the centrosome.
This study looks at the impact of Vif localization on Apobec3G degradation and
virion packaging. In Chapter II , the viral isolate from LTNP4 was shown to contain a
KKRK motif in the central region. Phenotypic studies showed that this motif
, a
common nuclear localization signal , was capable of mediating nuclear localization of the
Vif protein. Viral constructs demonstrated a reduced infectivity when this KKRK motif
was present. These observations led to the hypothesis that KKRK Vif located in the
nucleus would not be able to mediate degradation of the cytoplasmically located
Apobec3G. This would leave a free pool of Apobec3G in the cytoplasm where it could
interact with NC and be packaged into the virion where it would disrupt reverse
transcription in the target cell , rendering the virus less infectious.
B. Subcellular localization patterns of Vif in infected cells
A previous study indicated that NL4.3/KKRK Vif was nuclear and exhibited
reduced infectivity compared to that of NL4.3/WT. However, tagged Vif proteins were
transfected into cells to assess localization. To confirm that the previously reported Vif
localization patterns are the same during an infection , the subcellular distribution of
NL4. 3/WT and NL4.3/KKRK Vifin infected GHOST-X4 cells were determined (Figure
1A). The NL4.3/KKRK Vif staining pattern demonstrates an area of intense staining
surrounded by a less intense , dispersed region of staining (panel I). The fluorescent
intensity profile (panel II) gives a topographical rendering of the most intense areas of
stain. This again shows that there exists a region of intense staining surrounded by a
much less intense , more dispersed stain. The intensity profile coupled with the overlay of
Vif and DAPI (panel II) show that the most intense area of Vif staining occurs in the
nucleus. The NL4. 3/WT Vif staining shows a dispersed stain throughout with a
concentrated area of high intensity in the perinuclear space (panel IV). Based on this and
the overlay of Vif with DAPI (panel VI), it is apparent that the intense area of Vif stain is
in the cytoplasm , with an intense area in the perinuclear space and less intense areas of
staining extending toward the cell membrane. The NL4.3/WT Vif showed the expected
predominant cytoplasmic partitioning, while the NL4.3/KKRK Vif demonstrated an
aberrant localization phenotype with the nuclear compartment being enriched in Vif
versus the cytoplasm.
The infection of GHOST-X4 cells provides a clearer picture of the localization of
Vif in a setting where all viral proteins are present. However, GHOST-X4 cells are not
natural target cells for II V - I infection. Therefore , the staining pattern of the NL4. 3/WT
and NL4.3/KKRK Vif proteins in infected T cells was examined. The T cell line HUT78
was infected with NL4.3/WT or NL4. 3/KKRK virus derived from permissive Hela cells.
T cells have limited cytoplasmic space with large nuclei , therefore cytoplasmic staining is
not as clear as it was in the GHOST -X4 cells. However, there is an absence of Vif stain
throughout most of the nucleus in the NL4.3/W cells (panel IX) with cytoplasmic
staining apparent when the Vif and nucleus images are overlaid (panel X). The
NL4. 3/KKRK infected cells demonstrate an opposite staining pattern. Here, it is clear
that the nucleus is intensely stained throughout for Vif with some staining in the
cytoplasm (panel VII and Vll).
NL4.3/KKRK Vif and NL4.3/WT Vif transfected Hela-Apo cells were also
differentially lysed for subcellular fractionation analysis. Both the nuclear and post-
nuclear fractions were separated on a SDS-PAGE gel and probed for Vif signal. Again
the NL4.3/W Vif shows a strong localization in the post-nuclear, cytoplasmic
compartment. However, the NL4.3/KKRK Vif preferentially partitions to the nuclear
fraction (Figure 4. 1B). Fractionation and loading controls confirm that the observed
localization patterns are not due to cross-contamination of the nuclear compartment
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Figure 4. 1: (A). Localization of NL4.3/W or NL4.3/KKRK Vif in infected cells.
GHOST-X4 cells were infected with NL4.3/W or NL4.3/KKRK and stained for Vif
three days post- infection. Vif staining patterns show that both the NL4.3/KKRK (panel I)
and NL4.3/W (panel IV) signals have distinct areas of intense stain surrounded by more
diffuse areas. Panels II and V are intensity topography maps that render the most intense
regions of stain in three dimensions. The overlay of Vif stain with DAPI revealed a more
concentrated nuclear stain for NL4.3/KKRK (panei II) compared to the intense
perinuclear stain apparent for NL4.3/W (panel VI). HUT78 cells were infected with
NL4. 3/WT or NL4. 3/KKRK and stained as above (panels VII-X). NL4.3/KKRK Vif
shows staining throughout the cell (panel VII). The NL4.3/W Vif stain shows an area
of exclusion surrounded by an area of staining (panel IX). The overlays of Vif stain with
DAPI show that NL4. 3/KKRK Vif is present in the nucleus (panel VII) while
NL4. 3/WT appears to be excluded from the nucleus (panel X) in infected HUT78 T cells.
(B). Hela-Apo cells were transfected with NL4.3/WT or NL4.3/KKRK and lysed into a
nuclear and post-nuclear fraction , immunoprecipitated , and resolved on a SDS-PAGE
gel. Blots were probed for Vif (upper panel) or tubulin (lower panel). For the Vif panel
lanes 1 and 2 are the nuclear and cytoplasmic fractions of uninfected Hela-Apo, lanes 3
and 4 are the NL4.3/KKRK and NL4.3/WT nuclear fractions , lanes 5 and 6 are the
NL4. 3/KKRK and NL4.3/WT cytoplasmic fractions. The blots were also probed for
tubulin as control for lysis and sample loading with lanes 1-3 being the uninfected,
NL4. 3/KKRK , and NL4.3/WT nuclear fraction and lanes 4-6 being the uninfected
NL4; 3/KKRK, and NL4. 3/WT post-nuclear fraction.
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during lysis or unequal sample loading. Together with the staining information , this
confirms that NL4.3/W Vif is cytoplasmic while NL4.3/KKRK Vif is nuclear.
c. Vif mediated degradation of Apobec3G
Since the NL4. 3/KKRK Vif demonstrates an aberrant localization pattern and is
less infectious, its ability to mediate degradation of Apobec3G was examined. 
cytoplasmic localization of Vif is important for Apobec3G degradation , which in turn
influences infectivity, then NL4.3/KKRK should be impaired in its ability to degrade
Apobec3G. A lack of Apobec3G degradation indicates the presence of either a non-
functional Vif that cannot bind Apobec3G or a functional Vif that is binding competent
but not accessible to the Apobec3G protein at a high enough concentration to mediate
degradation.
For the Apobec3G degradation assay, Hela cells, which contain no endogenous
Apobec3G , were co-transfected with the NL4.3/W or NL4.3/KKRK construct and
either GFP-vector or GFP-Apobec3G plasmid. Two days post- transfection , %GFP+ cells
were enumerated by FACS. This value was taken as the baseline reading for GFP-vector
or GFP-Apobec3G expression. Using GFP fluorescence as a surrogate marker for
Apobec3G degradation , the loss of GFP signal was followed over the next four days.
Figure 4.2A shows the GFP signal over time for each of the cultures. Both the control
GFP-vector and GFP- Apobec3G showed no significant fluctuation in o/GFP+ cells over
time in the absence of any Vif. Some loss of signal was detected for the GFP-vector and
GFP-Apobec3G plus NL4.3/KKRK cultures. However, the fold reduction in signal for
the GFP-Apobec3G was not significantly different from that of the GFP-vector (p:;.05),
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indicating that there was no active degradation of GFP-Apobec3G. For the NL4.3/W
cultures , loss of GFP signal was elevated in both the GFP-vector and GFP-Apobec3G co-
transfections to levels significantly above those in the control transfections. Importantly,
the fold reduction in %GFP+ cells was almost twice as high for the GFP-Apobec3G
sample as it was for the GFP-vector sample. This difference is clearly shown in Figure
2B where the GFP-Apobec3G values have been normalized against GFP-vector. The
normalized fold reduction for GFP-Apobec3G in the NL4. 3/KKRK co- transfection
remains at or around one over the course of sampling. The normalized fold reduction for
the GFP-Apobec3G in the presence of NL4.3/WT is slightly elevated at day 2, and is
significantly elevated at day 4.
It is clear that NL4.3/WT Vif is capable of degrading GFP-Apobec3G at a high
level on day four. To conclusively show this, the fold reduction on day four for GFP-
Apobec3G alone or with either construct was compared. As can be seen in Figure 4.
the difference between loss of signal in GFP-Apobec3G and GFP-Apobec3G plus
NL4.3/KKK is minimal. There is a clear and statistically significant difference (p.:. 05)
between the fold reduction in GFP signal when the GFP-Apobec3G alone is compared to
the GFP-Apobec3G plus NL4.3/WT. The inability to degrade Apobec3G demonstrated
by the NL4. 3/KKRK Vif could lead to the packaging of Apobec3G in NL4.3/KKRK
virions resulting in non- infectious virions.
D. Binding of NL4.3/WT and NIA. 3/KKRK Vif to Apobec3G
Based on the above data, NL4.3/KKRK Vif does not mediate degradation of
Apobec3G. This can be attributed to either the localization phenotype of NL4.3/KKRK
103
Figure 4.
-+ 
Apobec3G
-
GFP
GFPjKKRK
Apobec3GjKKRK
-+GFPjWT
Apobec3GjWT
Days
104
:. 
1.5
't 
Days
Apobec3GjKKRK -. Apobec3GjWT 
105
18APobeC3G 8Ap bec3G+KKRK 8 Apobec3G+WT I
106
Figure 4.2: Degradation of GFP-Apobec3G by NL4.3/KKRK and NL4.3/W. (A). Hela
cells were co- transfected with GFP vector or GFP-Apobec3G plus an empty vector
NL4. 3/KKRK , or NL4. 3!WT. The number of GFP+ cells was enumerated by FACS for a
7 day period following transfection. All transfections were normalized to day two post-
transfection and the fold reduction of GFP over the following five days was determined.
Data shown is the average of three independent experiments.
(B). To determine the reduction of GFP-Apobec3G independent of normal loss of GFP
fluorescence over time , fold reduction of GFP-Apobec3G cotransfectants was normalized
against GFP vector cotransfectants. Data shown is the average of three independent
experiments.
(C). The peak value for fold reduction of GFP-Apobec3G for GFP-Apobec3G+vector,
GFP-Apobec3G+NL4.3/KKRK, and GFP-Apobec3G+NL4.3!WT on day four is shown.
The fold reduction was statistically significantly different between GFP-
Apobec3G+vector and GFP-Apobec3G+NL4.3/W (po:.05), but not between GFP-
Apobec3G+vector and GFP-Apobec3G+NL4.3/KKK (p::.05).
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Vif or NL4.3/KKRK Vif may not be capable of directly interacting with Apobec3G. To
address the possibility that NL4. 3/KKRK Vif is a binding mutant , an in vitro pull-down
assay using His- tagged rKKRK- Vif or rWT - Vif proteins with lysates from GFP-
Apobec3G transfected Hela cells was performed. Relative amounts of Vif and
Apobec3G were determined by Western blot and densitometry analysis (Figure 4. 3).
The results showed that rKKRK- Vif is capable of binding Apobec3G more efficiently
than rWT - Vif in an in vitro setting. Therefore, NL4.3/KKRK Vif is not a binding mutant
for Apobec3G.
E. Co localization of Apobec3G with NL4.3/WT or NIA. 3/KKRK Vif
In light of the above finding that NL4.3/KKRK Vif is competent for binding to
Apobec3G , but can not mediate the degradation of Apobec3G, the localization patterns of
both NL4.3/KKRK and NL4.3/WT Vif proteins with Apobec3G were investigated to
determine if localization influences the ability of Vif to counteract Apobec3G.
Hela cells were co-transfected with NL4.3/KKRK or NL4.3/WT plasmid along
with GFP-Apobec3G plasmid , or with GFP-Apobec3G plasmid alone. Two days post-
transfection, cells were fixed and stained for Vif and the nucleus (Figure 4.4). In the
absence of Vif, the GFP-Apobec3G protein showed a punctate pattern that was dispersed
throughout the cytoplasm (panels I and II). However, when the GFP-Apobec3G protein
was co- transfected with NL4.3/WT, fewer cells expressing GFP-Apobec3G were
detected. In cells where signal was detected , the GFP-Apobec3G signal now occurred as
a compact aggregate in the perinuclear space (panel VI). The NL4.3/W Vif protein also
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Figure 4.3: Binding of Apobec3G by rKKRK- Vif and rWT - Vif. Lysates of Hela cells
transfected with GFP-Apobec3G were applied to columns of immobilized rKKRK- Vif 
rWT - Vif. The columns were eluted and purified rVif plus any interacting proteins were
run on a SDS-PAGE gel. The gel was subjected to Western blot using a Vif or
Apobec3G specific antibody to detect the GFP-Apobec3G fusion protein. The ratio of
Vif to Apobec3G for each rVif was determined using the Kodak imaging software.
rKKRK- Vif was found to have a Apobec3GNif ratio of 0.93 indicating strong
interaction. The rWT - Vif exhibited an Apobec3GNif ratio of 0. 30 indicating a slightly
weaker interaction. No interaction was observed between Apobec3G and the empty
pHATll vector.
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exhibited a strong perinuclear, aggregated localization in these co- transfected cells (panel
VII). When the two signals are overlaid , it is clear that the GFP-Apobec3G and
NL4.3/WT Vif are colocalized as a perinuclear aggregate (panel VII). In a majority of
cells containing perinculear aggregates , the nucleus was invaginated in the area of the
aggregate, a hallmark of the aggresome. This formation of an aggresome may be
functionally important as a storage site for bound Apobec3G or, for
the recruitment of proteasomal machinery to degrade both proteins. When the GFP-
Apobec3G signal was determined in NL4.3/KKRK co- transfected cells, it demonstrated a
significantly different localization pattern. Here , the GFP-Apobec3G protein appears to
be dispersed throughout the cytoplasm with some areas of intense signal in the nucleus
(panel II). The cytoplasmic signal is dispersed in the region outside of the nucleus as
was seen in the cells where Vif was not expressed. The Vif immunostaining revealed that
NL4. 3/KKRK Vif was predominantly nuclear (panel IV) and that colocalization of GFP-
Apobec3G with NL4.3/KKRK Vif was less than that with NL4. 3/WT Vif. Additionally,
the limited area of GFP-Apobec3G colocalization with NL4. 3/KKRK Vif does not appear
as a perinuclear aggregate (panel V).
The images presented are representative of a series of images analyzed. In order
to address the question of colocalization in a more quantitative manner, the percent
colocalization for each set of transfections was calculated. Figure 4.3B shows that while
the NL4.3/W Vif efficiently colocalizes with the GFP-Apobec3G with 79% overlap, the
NL4. 3/KKRK exhibits only a 51 % overlap. This difference in overlap is significant
(po:.005) and could be a reason for the observed inhibition of NL4.3/KKRK mediated
Apobec3G degradation.
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While the differences in the colocalization were clear, there was stil
colocalization of GFP-Apobec3G with NL4.3/KKRK Vif. If the colocalization was
occurring in the nucleus, this would leave a pool of free Apobec3G in the cytoplasm. To
determine where the colocalization was occurring, a region of overlap was created by
overlaying the Vif and Apobec3G images, and then subtracting out all light not
corresponding to the colocalizing areas. This region of overlap was then overlaid with
the phase image to determine if the colocalization was nuclear or post-nuclear (Figure
5A). The overlap of NL4.3/W Vif and Apobec3G is extensive (Figure 4.4B) and
occurs exclusively at a perinuclear site (panel IV). This is in agreement with previous
reports that the degradation of Apobec3G occurs via the proteasome pathway, which is
known to be concentrated in the perinuclear region (388, 389). The region of overlap
image for the NL4.3/KKRK Vif and GFP-Apobec3G was distinct from that of the
NL4. 3/WT Vif. Instead of an aggregated , perinuclear signal , the signal is a collection of
smaller foci (panel I). When this image is overlaid with the phase image (panel II), it is
clear that these small foci are concentrated in the nucleus with a very small, light area
dispersed around the nuclear envelope.
A quantitative analysis for this breakdown of colocalization was performed as
above. The region of overlap and DAPI nuclear stain were used to quantify where the
Vif and Apobec3G colocalization was occurring for each Vif construct. Figure 4.
shows that the colocalization that occurs between NL4. 3/WT Vif and GFP-Apobec3G is
almost exclusively cytoplasmic (88.2%) with minimal colocalization being detected in
the nucleus. This ratio is inverted for the NL4.3/KKK Vif with 88.6% of the
colocalization now occurring in the nucleus.
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This disparity in colocalization could impact the viral packaging of Apobec3G.
In the NL4.3/KKRK , cells some of the Apobec3G is sequestered in the nucleus. But the
remaining Apobec3G that does not colocalize with NL4.3/KKRK Vif exists as a
cytoplasmic pool of free Apobec3G that is available for packaging in the virion. In the
NL4. 3/WT cells there is no free Apobec3G in the cytoplasm for virion packaging as it is
completely sequestered in a perinuclear aggregate.
F. Packaging of Apobec3G in NL4.3/WT or NIA. 3/KKRK virions
Since NL4.3/KKRK Vif does not mediate degradation of Apobec3G, a free pool
of Apobec3G exists in NL4.3/KKRK transfected cells, and NL4.3/KKRK virions are less
infectious than NL4. 3/WT , it was important to determine if Apobec3G was being
packaged into NL4.3/KKK virions.
Virions were harvested from the supernatant of Bela cells co-transfected with
GFP-Apobec3G plus NL4.3/WT or NL4.3/KKRK and assayed for the amount of GFP-
Apobec3G packaged. Following concentration by ultracentrifugation and a p24 detection
assay, the virions were lysed and gels were loaded with equal amounts of p24 for each
sample. Levels of GFP-Apobec3G and p24 were determined by Western blot and
densitometry. The amount Qf GFP-Apobec3G packaged was established by normalizing
the GFP-Apobec3G signal to the p24 signal for each sample. As shown in Figure 4.
NL4.3/KKRK virions package Apobec3G at a 25-times higher level than NL4.3/WT
virions. This could be explained by the availability of Apobec3G in the cytoplasm of
NL4. 3/KKRK transfected cells. The packaging of Apobec3G into NL4.3/KKRK virions
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Figure 4.4: Colocalization of Apobec3G and NL4.3/WT or NL4.3/KKRK Vif. (A).
GFP-Apobec3G was transfected alone (panels I-II), or co-transfectedwith NL4.3/KKRK
(panels II-V) or NL4. 3/WT (panels VI-VII) into Hela cells. Two days post-
transfection , cells were stained for Vif and evaluated for colocalization of Apobec3G and
Vif. Panels I, III, and VI are the GFP-Apobec3G signal , panels IV and VII are Vif signal.
Panel II shows the overlay of GFP-Apobec3G and DAPI, demonstrating that Apobec3G
is distributed in the cytoplasm in the absence of Vif. Panel V is an overlay of
NL4. 3/KKRK Vif and Apobec3G signals showing that there are limited areas of
colocalization. The overlay of NL4.3/W Vif and Apobec3G signals (panel VII) reveals
an extensive colocalization of the signals in a perinuclear aggregate.
(B). Quantification of colocalization. The percent overlap for the GFP-Apobec3G and
NL4.3/KKRK Vif and GFP-Apobec3G and NL4. 3/WT Vif was determined using the
measure colocalization feature of MetaMorph. GFP-Apobec3G shows a 51 % overlap
with the NL4. 3/KKRK Vif and an 79% overlap with the NL4. 3/WT Vif (p-c.005). The
error bars represent standard deviation (n=5).
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Figure 4.5: Site of GFP-Apobec3G Vif colocalization. (A). The subcellular site of
colocalization for was determined by creating a region of interest image that showed only
the area where overlap occurred for NL4. 3/KKRK Vif and GFP-Apobec3G (panel I) and
NL4. 3fWT Vif and GFP-Apobec3G (panel II). This region of interest site was then
overlaid with the phase contrast image to determine the subcellular site of colocalization.
The overlay of the NL4. 3/KKRK Vif region of interest with phase (panel II) shows a
predominantly nuclear localization. The NL4.3/WT Vif region of interest overlay (panel
IV) shows an exclusively perinuclear aggregate.
(B). Quantification of subcellular site of colocalization. The percent distribution of
overlap for each construct was determined by comparing the region of interest to the
nuclear DAPI stain. For NL4.3/KKRK Vif colocalization with GFP-Apobec3G, 88.
of the overlap occurred in the nucleus. The NL4.3fWT Vif colocalization with GFP-
Apobec3G demonstrated a 11. 8% overlap in the nucleus with 88.2% of the overlap
occurring outside of the nucleus. The difference in localization is statistically significant
po:.0005. The error bars represent standard deviation (n=5).
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would result in reduced infectivity of NL4.3/KKRK compared to NL4.3/W, as has been
previously reported.
G. Discussion
The work presented here points to the critical nature of HIV - l Vif localization
during the viral life cycle. Previous work has detailed the importance of Vif interactions
with Apobec3G , here it is shown that Vif must be available in the cytoplasm to bind and
counteract the inhibitory effects of Apobec3G by preventing its packaging into the virion.
Although NL4. 3/KKRK Vif is expressed at a normal level and is fully capable of binding
Apobec3G in an in vitro setting, its aberrant localization during the viral life cycle
renders it less effective against Apobec3G, thus demonstrating that mislocalization of
HIV - 1 Vif is sufficient to confer a/) Vif phenotype.
Previous work on determinants of viral fitness in long-term non-progressors
presented in Chapter II, showed that the KKRK Vif mutation was capable of
mislocalizing Vif to the nucleus and rendering virions produced from non-permissive
cells significantly less infectious. The work presented here extends that study to include
analysis of the impact of mislocalization of Vif on its ability to neutralize the cellular
cytidine deaminase Apobec3G. NL4.3/KKRK Vif is mislocalized to the nucleus in
infected cells. This quarantining of Vif in the nucleus prevents it from interacting with a
significant amount of Apobec3G in the cytoplasm. Lack of interaction leads to
diminished Apobec3G degradation , which allows virion packaging of Apobec3G. When
Apobec3G is packaged into the virion , it can disrupt the reverse transcription process in
the target cell leading to a non-productive infection.
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It is also important to note that while the KKRK Vif mutation is being studied in
the context of Vif localization and its influence on function , this is the first report that
characterizes the impact of a naturally occurring Vif mutation on its ability to counteract
Apobec3G. While other studies have shown that naturally occurring Vif mutations can
diminish viral infectivity (31 , 82-84), this is the first study to directly assess the ability of
a naturally occurrng Vif mutant to interact with and degrade Apobec3G. Interestingly,
NL4. 3/KKRK virus does not have a complete !l Vif phenotype when spreading replication
assays are followed for a period in excess of one week. This could be due to the fact that
the NL4. 3/KKRK Vif retains the capacity to interact with Apobec3G and sequester some
of it into the nucleus. But, its altered subcellular localization does not allow
NL4. 3/KKRK Vif to access all of the Apobec3G, as seen in the NL4.3/WT Vif model
and a free pool of Apobec3G is still available in the cytoplasm. The eventual emergence
of replication competent NL4. 3/KKRK vims after several days in tissue culture could
indicate that in some cells, enough interaction is occurring with Apobec3G and infectious
virus is produced. This highlights the critical balance between Vif and Apobec3G that
must be maintained during virus assembly.
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Figure 4. 6: Packaging of Apobec3G into the virion. Virus produced by co-transfection
of GFP-Apobec3G and NL4.3/KKRK or NL4.3/W was harvested , concentrated , and
lysed. Virion associated proteins were resolved on an SDS-PAGE gel. Levels of virion
associated Apobec3G and p24 protein were determined by Western blot. The ratio of
p24 to Apobec3G was calculated using the Kodak imaging software. The Apobec3G
packaged into the NL4.3/KKRK virion at a ratio of 0. , the NL4.3/W virion packaged
Apbec3G at a ratio of 0.02 which is not above the negative control lane using culture
supernatant from Hela transfected with GFP-Apobec3G vector only.
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CHAPTER V
HIV - 1 VIF SEQUESTERS APOBEC3G INTO AGGRESOMES TO PREVENT
VIRION INCORPORATION OF APOBEC3G
A. Introduction
In light of the recent advances in determining Vif function, understanding the
mechanisms and pathways involved in Vif-Apobec3G interaction has become critical. It
has been shown that Vif is necessary for the proteasomal degradation of Apobec3G (329-
333, 352 , 361). Additionally, there is evidence that a direct interaction between Vif and
Apobec3G could inhibit Apobec3G function (334, 335). Both of these processes appear
to occur in the cytoplasm.
While the directed proteasomal degradation of Apobec3G has been the focus of
several recent studies , the ability of Vif to neutralize Apobec3G without degradation has
been noted , but remains poorly defined. The experiments presented in Chapters III and
IV demonstrate the importance of cytoplasmic localization of Vif during the viral life
cycle in preventing virion incorporation of the cellular inhibitory factor Apobec3G.
Interestingly, while conducting these experiments, it was found that Vif and Apobec3G
form perinuclear aggregates that resemble aggresomes. Recently, Rana s lab published a
similar observation of Vif-Apobec3G colocalization reminiscent of aggresomes (352). In
addition to that study, an earlier paper reported that Vif localized in a perinuclear space,
surrounded by a vimentin cage (351), a typical aggresome structure (390). Taken
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together with previous observations, it is proposed that the observed Vif-Apobec3G
perinuclear aggregates are aggresomes and that the formation of aggresomes could be
mechanistically important for Vif function. This second inhibitory effect on Apobec3G
would be achieved by sequestering it into an aggresome in the perinuclear space to
prevent Apobec3G interaction with NC and subsequent virion packaging.
B. Vif-Apobec3G aggregates contain ubiquitin
If the Vif-Apobec3G perinuclear aggregates are aggresomes, then aggresome
markers such as ubiquitin should also be present in the aggregates (390, 391) To
determine if ubiquitin was present in the perinuclear aggregates, Hela cells were co-
transfected with Apobec3G and NL4.3/WT and analyzed for Apobec3G and ubiquitin
colocalization in perinuclear aggregates (Figure 5.1). Imaging revealed that when GFP-
Apobec3G is transfected into Hela cells, it is distributed throughout the cytoplasm
(panels I and II), as previously observed. However , when GFP-Apobec3G is co-
transfected with NL4.3/WT, cells exhibiting perinuclear aggregates of Apobec3G are
detected (panel IV). Ubiquitin staining reveals that the perinuclear aggregates contain
ubiquitylated protein (panels V and VI). This observation is in agreement with several
recent studies that have shown Apobec3G ubiquitination when Vif is present (336, 337
339) .
In addition to detection of the aggresome marker ubiquitin , analysis of the phase
image shows a dense body in the perinuclear region (panel VII) that overlaps with the
Apobec3G (panel VII) and ubiquitin signals (panel IX). Such bodies are not present in
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GFP-Apobec3G transfected cells in the absence of Vif (panel III). Again , dense
perinuclear bodies are indicators of aggresome formation (392).
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Figure 5. 1: Apobec3G perinuclear aggregates recruit ubiquitin, Hela cells were
transfected with GFP-Apobec3G (panels I-III) or cotransfected with NL4.3/WT and
GFP-Apobec3G (panels IV-IX). The GFP-Apobec3G signal is cytoplasmically
distributed in the absence of Vif (panel I). Overlaying the Apobec3G signal with DAPI
nuclear stain (panel II) or with DAPI and phase (panel II) shows that there is no
Apobec3G in the nucleus. Cotransfected cells were stained for ubiquitin (panel V). The
GFP-Apobec3G signal demonstrates a perinuclear aggregate (panel IV). When the
Apobec3G and ubiquitin signals are overlapped , it is clear that ubiquitin is also present in
the perinuclear aggregate (panel VI). A dense structure is apparent in this cell under
phase (panel VII) that colocalizes with the aggregated Apobec3G (panel VII) and
ubiquitin (panel IX) signals in this cell.
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c. Vif and Apobec3G form aggresomes
While the presence of ubiquitin in the aggregates does suggest aggresome
formation , its presence alone is not sufficient to confirm this. It is possible that these
aggregates are just colocalizing Vif and ubiquitylated Apobec3G , not specifically formed
aggresomes. To address this possibility, the presence the aggresome assembling protein
HDAC6 (392, 393), was determined. The Hela-Apo cell line that is stably transfected
with Apobec3G to allow for constitutive expression of Apobec3G was used. Hela-Apo
cells were transfected with NL4.3/WT and stained for Vif plus HDAC6.
Transfection of Hela-Apo with NL4.3/WT again demonstrated the presence of
perinuclear aggregates containing Vif (Figure 5. , panels I and V). When cells were
stained for the ubiquitously expressed HDAC6 , it was found distributed throughout the
cytoplasm for most of the cells (panel II). However, in cells containing Vif aggregates
HDAC6 also demonstrated a perinuclear , aggregated staining (panel II). When the Vif
and HDAC6 signals were overlaid, it was clear that Vif and HDAC6 were present in the
same perinuclear aggregate (panel III). The aggregate of Vif and HDAC6 is
distinguishable as a dense structure in the phase images (panel IV). The presence of the
specific aggresome marker HDAC6, in addition to ubiquitin , demonstrate that the Vif-
Apobec3G aggregates are aggresomes.
D. Vif-Apobec3G aggresomes are regulated by the microtubule network
Aggresomes form in the cytoplasm and are then transported to the perinuclear
region via the microtubule network (390, 393). Inhibition of microtubule trafficking by
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Figure 5.
Figure 5.2: Vif-Apobec3G aggregates are aggresomes. Hela-Apo cell lines were
transfected with NL4.3/WT and stained for HDAC6 (panel I) or Vif (panel II). Both
signals demonstrated an aggregated signal that colocalized when the images were
overlapped (panel III). A dense structure is also present under phase (panel IV).
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nocodazole treatment, which induces microtubule network collapse, causes dispersion of
the aggresome into smaller vesicles that are excluded from the perinuclear space and
J -
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redistributed throughout the cytoplasm (390, 393). While it was evident that Vif and
Apobec3G were forming aggresomes, it was unclear whether these Vif induced
aggresomes behaved in a manner analogous to aggresomes formed by cellular proteins.
The role of microtubule trafficking in Vif-Apobec3G aggresome formation was
investigated by exposing Hela cells transfected with NL4.3/W to nocodazole (Figure
3). First, the impact of aggresome formation on micro tubules was assessed by staining
transfected cells for Vif and tubulin. In all cells , including those that exhibited Vif
aggresomes, the tubulin network was not perturbed (panels I and II). However, when the
cells were treated with nocodazole prior to fixation, the microtubule network collapsed
and tubulin staining was now present as an intense signal in an area consistent with the
microtubule organizing center (MTOC) (panel VI). While this result is expected for
nocodazole treated cells, a more interesting observation is the dispersal of Vif stain in
these cells (panel V). The Vif aggregate is not completely disrupted, but it is no longer
located in the perinuclear space and it has begun to dissipate with the emergence of
smaller , punctate foci rather than the tight, aggregated signal previously seen (panel V).
To determine if this dispersal of Vif signaling is an artifact of treatment with
nocodazole , Hela cells were transfected with a DsRed- Vif protein and treated with
leptomycin. Leptomycin inhibits nuclear shuttling by preventing nuclear export and
trapping shuttling proteins in the nucleus. Some groups have proposed that Vif is capable
of shuttling into and out of the nucleus. The use of leptomycin treatment provides a
control for the nocodazole experiment and allows for investigation of the proposed
f:'
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nuclear shuttling capacity for Vif. In cells transfected with the DsRed- Vif construct that
were untreated , Vif aggregates in the perinuclear region were detected (panel X). In the
presence of leptomycin treatment , Vif aggregates were still detected in a perinuclear
region (panel XII). These results show that aggresome formation and disruption are not
experimental artifacts and are controlled by the microtubule network. Additionally, it
argues against a nuclear shuttling function for Vif.
E. Vif mediates aggresome formation
While the experiments in Hela cells demonstrate that Vif and Apobec3G form
aggresomes, the question of which component was mediating aggresome formation still
remained. To determine whether Vif or Apobec3G was driving aggresome formation
pull-down assays using rVif or rA3G were performed with lysates from H9 that
endogenously express Apobec3G or H9 infected cells. rVif or rA3G were immobilized
on columns and allowed to incubate with celllysates. The rVif or rA3G were eluted
from the column , along with any bound protein , and equal amounts of protein for each
eluted sample were resolved on a SDS-PAGE gel. A total cell lysate and vector only plus
lysate were included as controls. Blots were probed with a-Hsp70 , a-vimentin , or a-
HDAC6. Additionally, the blots were also probed with a-Apobec3G or a- Vif 319mAb
to confirm expression.
Hsp70 is a cellular chaperone that is recruited to the aggresome along with
ubiquitin and the proteasome (389, 393). The Hsp70 blot (Figure 5.4, middle panel)
showed that while Apobec3G is capable of interacting with Hsp70 (lane 2), this
interaction is enhanced when the cell is infected and Vif is present (lane 3). When Vif is
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Figure 5. 3: Vif-Apobec3G aggresomes are regulated by the microtubule network. Hela
cells were transfected with NL4. 3/W and stained for Vif (panels I and V) or tubulin
(panels II andVI). The cells in panels V-VIII were treated with 10f-M nocodazole for 3
hours. When the microtubule network is intact (panel II), aggregated Vif stain can be
detected (panel I) with the characteristic nuclear invagination (panel II) and dense phase
structure (panel IV). When the cells are treated with microtubule depolymerizing drug,
the microtubule network collapses (panel VI) and the Vif signal is displaced from the
perinuclear space to a cytoplasmic location and the signal begins to disperse (panel V).
The nucleus is no longer invaginated (panel VII) and there are now two dense phase
structures corresponding to the collapsed tubulin signal and displaced Vif signal (panel
VIII). In panels IX-XII , Bela cells were transfected with a DsRed- Vif construct and
treated with 5ng/mlleptomycin for 2.5 hours (panels XI and XII). Vif is capable of
forming perinuclear aggregates in the absence (panel IX, arrows) or presence (panel XI
arrow) of leptomycin. In both cases, invagination of the nucleus is also detectable
(panels X and XII, arrows).
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used as the bait protein , an equal amount of Hsp70 is detected from pulldowns of infected
celllysates (lane 5). The strongest signal is obtained when rVif is incubated with
uninfected H9 cells (lane 6). This indicates that both proteins bind Hsp70, but that the
presence of Vif enhances interaction with Hsp70.
The HDAC6 blot (Figure 5.4, upper panel) provided further insight into this
question of whether Apobec3G or Vif were mediating the aggresome formation. HDAC6
regulates aggresome formation , so binding to HDAC6 would be the initial step in
forming the aggresome. Neither of the rA3G lanes were capable of interacting with
HDAC6 (lanes 2 and 3). However, the rVif proteins were competent for HDAC6
binding. Interestingly, we again detect a stronger interaction when uninfected H9 lysates
were used (lane 4). These observations were unexpected in terms of uninfected cell
lysates giving stronger signals. However, the lysis that was performed does not involve
the extraction of detergent resistant fractions , which is where aggresomes are located.
1.:
Therefore , we propose that infected cells having preformed aggresomes located in
detergent resistant compartments have less free HDAC6 or Hsp70 available in the
lysates. Taken with the observations above , we propose that Vif interacts with HDAC6
to drive aggresome formation.
Pull-down assays were also performed to determine if the previously reported
observation of Vif interaction with vimentin held true in our system (351) Permissive
SupTI or non-permissive HUT78 T cells, the stably transduced cell lines SupTlxVif or
HUT78xVif, or infected SupTI or HUT78 T cells were lysed and incubated with
immobilized rVif. The eluted proteins were gel resolved and the blots were probed with
a-vimentin (Figure 5.4, lower panel). Vif was able to pull down vimentin from each of
Figure 5.4
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Figure 5.4: Vif mediates aggresome assembly. rApobec3G or rVif were expressed and
immobilized on a TALON column. For the Hsp70 and HDAC6 blots , lysates of H9
infected (*) or uninfected cells were added to the column , eluates were recovered , and
equal amounts of protein were resolved on a SDS-P AGE gel. A cell lysate that was
applied to a vector only column (lane 1) and a cell lysate that was not run over a column
(lane 6) were included as controls. For the vimentin blot, uninfected HUT78 (lane 1) or
SupTl (lane 4), HUT78xVif (lane 2) or SupTlxVif (lane 5), or infected HUT78 (lane 3)
or SupTI (lane 6) lysates were added to immobilized Vif columns and processed as
above. Blots were probed for HDAC6 (upper panel), Hsp70 (middle panel), or vimentin
(lower panel).
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the samples, regardless of the presence of Apobec3G or other viral proteins. However
the strongest signal was from HUT78 cells, suggesting that the presence of Apobec3G
increases the affinity of Vif for vimentin. Again the signal is stronger in uninfected cells,
as was seen with Hsp70, perhaps indicating that vimentin is more accessible from in cells
where Vif is not being expressed and aggresomes are not being formed. This shows that
Vif and vimentin can interact in vitro in addition to the previous reports demonstrating an
interaction in the cell.
F. Functional relevance of aggresome formation
The experiments detailing colocalization of Vif, Apobec3G, and aggresome
markers suggest that Vif forms an aggresome and can recruit Apobec3G into that
aggresome. The question remained as to whether formation of this aggresome had any
functional relevance for Vif.
To address this, the non-permissive CEM cell line that expresses Apobec3G and
its permissive derivative CEM-SS that does not express Apobec3G were infected , treated
with aggresome disrupting drugs, and assayed for viral infectivity. Two days post-
infection, cells were washed extensively and treated with the proteasome inhibitor
lactacystin , the microtubule depolymerizing drug nocodazole, or Scriptaid , an inhibitor of
HDAC6. The cells were allowed to produce virus in the presence of the drugs for
eighteen hours. Culture supernatants were harvested and used in the GHOST-
infectivity assay. When cultures were normalized against infection mediated by
untreated cell supernatants, it was clear that each of the drugs was inhibitory in the CEM
cells with varying efficacy (Figure 5.5, panel A).
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However, the full extent of this inhibition was revealed when the normalized
inhibitions for CEM cells were compared to normalized CEM-SS infections (Figure 5.
panel B). This shows that-while lactacystin does have inhibitory effects on virus
produced from CEM cells , it also has modest inhibitory effects on virus released from the
permissive line CEM-SS. Nocodazole and Scriptaid also show diminished infectivity for
virus released from CEM cells , but both treatments actually enhance infectivity for CEM-
SS cells. By comparing the effect of the drug treatments on both cell types, the
nocodazole and Scriptaid treatments appear to have more of an impact on virus
infectivity than lactacystin treatment. While this could be due to a suboptimal dose of
lactacystin or be attributed to the high levels of Apobec3G used in this study, it is still
evident that nocodazole and Scriptaid treatment dramatically reduce viral infectivity
when Apobec3G is present.
G. Discussion
While previous studies suggested that Vif and Apobec3G may form aggresomes
here it is shown that Vif can bind Apobec3G and form an aggregated structure with
characteristics of a cellular aggresome including association with ubiquitin, vimentin
Hsp70, and HDAC6. Apobec3G present in the aggresome is sequestered to a perinuclear
region away from the virus assembly site. The potential functional relevance of Vif
mediated aggresome formation is demonstrated when producer cells are treated with
drugs to disrupt the proteasome or aggresome formation. In this study, disrupting
aggresome formation had more of an impact on infectivity than inhibiting the
proteasome.
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Figure 5.5: Disrupting aggresome formation reduces infectivity. (A). CEM or CEM-
cells were infected with NL4.3/WT for two days before being washed and treated with
lactacystin, nocodazole, or Scriptaid for ISh. Equal amounts of p24 were used to infect
GHOST-X4 reporter cells. Three days post- infection , the number of GFP+ cells was
determined by FACS analysis. Infectivities were normalized against virus from untreated
cells for each cell type. (B). CEM infectivity was then normalized against CEM-
infectivity for each treatment tested (n=2).
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Aggresome formation has been the focus of several recent studies as aggresomes
are believed to participate in pathogenesis of diseases such as Alzheimer s (394),
Huntington s (395), and Parkinson s (396). It has been shown that the aggresome is
formed in response to proteasome inhibition or when the proteasome becomes saturated
and misfolded protein continues to accumulate in the cell (390, 391). It is believed that
aggresomes serve as long term storage sites for misfolded protein to protect the cell from
the adverse effects of misfolded proteins in the cytoplasm. The aggresome localizes to a
perinuclear site where it can eventually access the proteasome machinery (389, 397).
In addition to these studies , other work has shown that some viral systems are
involved in protein sequestration by aggresome-like cytoplasmic body formation.
Adenovirus EIB inhibits p53-mediated apoptosis by binding and sequestering p53 into a
cytoplasmic body that resembles an aggresome , although it does not have all of the
attributes of a cellular aggresome formed in response to misfolded protein stress (398).
Also, a C- terminal fragment of the cellular protein TSG101 is able to block retrovirus
budding for PT AP- and PPPY -dependent retroviruses by sequestering viral Gag proteins
into an aggresome like cytoplasmic aggregates (399). In both cases, it is believed that
one protein is prone to aggregation and actively recruits the substrate protein into an
aggresome structure to inhibit its function in the cell. This model is similar to the one we
are proposing for Vif induced aggregation of Apobec3G in order to sequester Apobec3G
away from the virus assembly site.
Vif aggregation can be seen both in the presence and absence of Apobec3G, while
Apobec3G aggregation occurs only when Vif is present. This observation is supported
by the finding that Vif interacts with the aggresome assembling protein HDAC6. Several
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lines of evidence have suggested that Vif is inherently unstable and could be prone to
aggregation based on this instability. First, the intracellular half-life of soluble Vif is
very short as it is rapidly degraded by the proteasome or shuttled into more stable
complexes that associate with the cytoskeleton (400). Additionally, Vif is a highly basic
protein with a predicted pI of around 9.
http://prospector.ucsf.edu/ucsfbin4.0/msdigest.cgi) . Our experiences in attempting
to overexpress rVif in vitro revealed that Vif is prone to forming insoluble aggregates at
neutral pH , which may indicate a tendency to aggregate in the cell where the cytoplasmic
environment is also around neutral pH (personal communication , Jared Auclair
University of Massachusetts Medical School). All of these observations suggest that Vif
is unstable in the cell and is prone to rapid degradation due to unfolding or misfolding.
We propose a model whereby Vif is inherently unstable and prone to aggregation.
When Apobec3G is present, Vif interacts with Apobec3G and recruits it into the
aggresome structure. This sequestration would effectively deplete the pool of free
Apobec3G available in the cytoplasm for interaction with nucleocapsid and subsequent
virion packaging. Having an aggresome structure available to sequester Apobec3G and
supplement the direct proteasomal degradation of Apobec3G would confer an advantage
to the Vif protein as it would have a means of storing Apobec3G while it also actively
directed its degradation. If the proteasome became saturated during the viral life cycle
the aggresome sequestration pathway would stil limit Apobec3G virion packaging and
perhaps eventually lead to proteasomal degradation. Wichroski et al. has recently
demonstrated the ability of Vif to sequester Apobec3G into vimentin caged , perinuclear
aggregates when proteasome function is impaired or when the Vif Cl14S mutant that is
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unable to interact with the EloBC-Cul5-E3 ubiquitin liagse complex to mediate
proteasomal degradation of Apobec3G are used.
Alternatively, the existence of two distinct Vif pathways for Apobec3G
neutralization may be due to separate pools of Apobec3G in the cell that are accessible by
different means. This is not unique as the MDM2-p53 interaction in cells can be
disrupted by two separate , independent mechanisms under different conditions (344). Vif
may utilize the different pathways, either the Cul5 complex assembly or HDAC6
mediated aggresome pathway, to access and neutralize the different stores of Apobec3G.
The existence of different forms of Apobec3G has been suggested in the Wichrowski
study where they detected Apobec3G as both a dispersed stain throughout the cytoplasm
as well as in specific cytoplasmic bodies. Also , it has recently been proposed that
Apobec3G can exist in both high and low molecular weight complexes in the cell (Retro
conference).
This bimodal action of Vif may be regulated by its phosphorylation state.
Recently, Mehle et al. found that unphosphorylated , but not phosphorylated Vif was
capable of interacting with the EloBC-Cul5-E3 ubiquitin ligase complex that is
responsible for directing the degradation of Apobec3G via the proteasome. The authors
of that study proposed that Vif regulation by phosphorylation could indicate the existence
of an alternative, phosphorylated form of Vif that could stil bind Apobec3G
, but might
sequester Apobec3G in a distinct subcellular compartment rather than direct its
degradation (338). The phosphorylation state of Vif may influence its ability to bind
either the EloBC complex or HDAC6 and allow Vif to exploit distinct pathways for
Apobec3G neutralization simultaneously in a synergistic fashion.
- .
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The work presented in Chapter V shows that Vif is capable of neutralizing
Apobec3G via a distinct pathway involving direct binding and sequestration of
Apobec3G into an aggresome structure. The aggresome structure is formed and stored in
the cytoplasm , again highlighting the critical importance of Vif localization in the
cytoplasm during infection. Having a second , complementary pathway for Apobec3G
neutralization may be important for Viffunction depending on the phosphorylation state
of Vif, the existence of discrete pools of Apobec3G , and the activation state of the cell.
This alternate pathway may allow Vif to access secondary sources of Apobec3G or to
provide long- term storage of Apobec3G when the proteasome is saturated or when
Apobec3G levels are in excess.
144
CHAPTER VI
DISCUSSION
A. Thesis Overview
Recent work in the HIV - 1 Vif field has focused on the interaction of Vif with the
cellular protein Apobec3G. If Apobec3G is packaged in the HIV- 1 virion , it inhibits the
reverse transcription process in the target cell and effectively disrupts the viral life cycle.
Vif counteracts Apobec3G by preventing its virion incorporation. This can be achieved
by two pathways, recruiting Apobec3G to a Vif-Cu15 ubiquitin ligase complex for
directed proteasomal degradation of Vif and Apobec3G (33l-333) or the direct binding of
Vif to Apobec3G and sequestration of Apobec3G away from the virus assembly site
(334 335, 338). In either case , the objective of Vif is to limit the amount of free
Apobec3G in the cytoplasm that is available to bind the HIV - 1 nucleocapsid and be
packaged into the virion. The work presented here has focused on the subcellular
localization of Vif during the viral life cycle and how this impacts the ability of Vif to
neutralize Apobec3G by either pathway.
As shown in Chapter II , the localization of HIV - 1 Vif in the cytoplasm is
extremely important for the production of infectious virus. Here , a naturally occurring
Vif mutant was identified and it was demonstrated that aberrant localization of Vif in the
nucleus resulted in the production of significantly less infectious virions. These initial
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observations suggested that Vif must be present in the cytoplasm to allow for production
of infectious virions.
The initial work presented in Chapter II highlighting the importance of Vif
localization during the viral life cycle was extended in Chapter IV to determine if Vif
localization influenced its ability to neutralize Apobec3G and prevent its incorporation
into the virion , thus explaining the observed defect in virus infectivity. Here , the
localization mutant identified in Chapter II was compared to a wild- type Vif protein in a
series of assays that examined colocalization of Vif and Apobec3G, degradation of
Apobec3G , and virion packaging of Apobec3G. The result of this study indicated that
the aberrantly located mutant protein was impaired in its ability to colocalize with
Apobec3G, direct Apobec3G degradation, and impair virion packaging of Apobec3G.
This confirmed the importance of cytoplasmic localization of Vif during the viral life
cycle to perform its function of Apobec3G neutralization.
During the course of the studies conducted in Chapters III and IV , perinuclear
aggregates of wild-type Vif and Apobec3G were observed. These observations, in
addition to the recent literature , suggested that Vif could also impair Apobec3G virion
incorporation independent of degradation , but rather by a direct binding. The result of
the experiments shown in Chapter V indicate that Vif can sequester Apobec3G into an
aggresome structure. This aggresome is located in the perinuclear space where it serves
as a long- term storage compartment during periods of proteasome malfunction or
saturation. While aggresome formation does not deplete Apobec3G from the cytoplasm
it does sequester it away from the virus assembly site which could also prevent virion
incorporation.
146
B. Rationale for studying HIV- J Vif subcellular localization
Several studies have demonstrated that Vif is cytoplasmically localized during the
viral life cycle (345-347). Additionally, it is known that Vif is a critical determinant of
viral replication and spread (73 , 79- 294-296). Many previous studies have utilized
Vif mutants that were truncated or had large regions deleted or substituted. Specific
amino acids and motifs were found to be important for Vif function. However
, no study
had fully considered the impact of Vif subcellular localization on function. In Chapter
III, the localization of HIV - 1 Vif was initially explored using an isolate from a highly
unique long-term non-progressor. This L TNP was shown to display a remarkable disease
course over a twenty year period of infection with stable CD4+ T cell counts, low to
undetectable viral loads, and an extremely difficult to culture virus. Based on these
characteristics, viral defects that contributed to the attenuated phenotype were
investigated. It was found that providing Vif in trans was sufficient to rescue this virus in
co-culture assays. This growth phenotype indicated that the vif gene may be defective.
Sequencing of the viral genome revealed that the virus harbored a unique set of mutations
resulting in a KKRK nuclear localization sequence being present in the central region of
the Vif protein. This NLS was found to be functional and sufficient to render the
majority of the Vif protein nuclear. Additionally, it was shown that the presence of this
unique KKRK motif rendered the virus significantly less infectious in a number of
infectivity assays. Based on the observed localization phenotype and infectivity defect of
the KKRK mutant , the importance.of Vif localization in terms of function was
determined.
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C. Cytoplasmic localization of HIV- / Vif is necessary for Apobec3G neutralization
Importantly, the defect in NL4.3/KKRK virus was only found when the virus was
produced from non-permissive cells. This indicated that subcellular localization of Vif
may be important for Vif-Apobec3G interactions since the replication defect was only
observed in the presence of Apobec3G. Since Apobec3G is cytoplasmically located
(307), and the NL4.3/KKRK Vif mutant is predominantly nuclear, it was proposed that
NL4. 3/KKRK Vif sequestered in the nucleus would not be available to interact with
Apobec3G.
The experiments conducted in Chapter IV were aimed at elucidating the
importance of the aberrant localization of NL4. 3/KKK Vif on Vif function. By
comparing the mislocalized NL4. 3/KKRK Vif to a normal NL4. 3/W Vif, a better
understanding of the importance of Vif localization during the viral life cycle could be
determined. First, the nuclear localization of NL4.3/KKRK Vif was confirmed in the
presence of other viral proteins to insure that the KKRK NLS was not occluded by Vif
interaction with other viral proteins. Also, the ability of NL4.3/KKRK Vif to bind
Apobec3G was determined. Since it is competent for interacting with Apobec3G in vitro,
but is unable to colocalize with Apobec3G iri the cell , it could be concluded that any
defect in NL4. 3/KKRK function is a localization defect.
At this point, it was clear from the work shown in Chapter III that NL4. 3/KKRK
viruses were significantly less infectious than NL4.3/WT viruses. Extensive work
present in the literature indicated that the difference between infectious and less
infectious virions, pertaining to Vif, is governed by thepackaging of Apobec3G in the
virion. Viruses with WT Vif proteins are able to inhibit Apobec3G packaging, whereas
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non-functional Vif proteins allow virion incorporation of Apobec3G. When the
NL4.3/KKRK and NL4.3/WT Vif proteins were compared in terms of their abilty to
mediate Apobec3G degradation , it was clear that NL4.
3/KKRK was not capable of
directing Apobec3G degradation. Since Apobec3G was not being degraded and there
was free Apobec3G available in the cytoplasm, virion packaging levels of Apobec3G
were compared. This provided the final piece of evidence that the NL4.
3/KKRK virus is
a Vif deficient virus since Apobec3G was packaged more efficiently into NL4.
3/KKRK
virions than NL4.3/WT virions. The packaging of Apobec3G into NL4.
3/KKRK virions
explains the diminished infectivity of these virions. This finding can be extrapolated to
explain one possibl defect in the L TNP4 virus. 
However, this one mutation alone
cannot fully explain the extreme attenuation of the L 
TNP4 virus as other mutations in Vif
and across the viral genome have been found, but remain to be investigated. Also, such a
remarkable disease course as the one exhibited by LNTP4 could only be attributed to
multigenic defects.
The data presented are in good agreement with the previously reported
cytoplasmic location of Vif. However, most of those observations were made prior to the
identification of Apobec3G as the cellular partner for Vif and the understanding of Vif
function. This study is unique in that it directly correlates subcellular localization and
Vif function by comparing distinctly localized Vif proteins and their ability to mediate
Apobec3G degradation and virion packaging. It conclusively shows that in addition to
understanding the structure-function relationship of Vif, one must also consider the
subcellular localization of the protein when defining function.
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This is also the first study to not only identify a naturally occurring Vif mutant
but to mechanistically define that mutant. Previous studies were unable to provide direct
evidence that their observed Vif mutants were functionally defective. Instead, those
studies relied on production of less infectious virus as a surrogate marker for Vif
function. Here , it has been shown that NL4. 3/KKRK Vif is aberrantly localized to the
nucleus and that this mislocalization is sufficient to render Vif non-functional and allow
packaging of Apobec3G leading to less infectious virus being produced.
Interestingly, this mutation does not render the virus completely replication
deficient. Rather, the virus appears to overcome the Vif defect after several rounds of
replication. The delay in kinetics raises some interesting points to consider. First , the
NL4. 3/KKRK Vif is capable of sequestering some Apobec3G in the nucleus. This
observation was made within the first few days of infection. Perhaps as the infection
continues , Vif continues to be produced at a high level while Apobec3G production
remains steady or declines. A recent study by Sheehy et al. did demonstrate that Vif
expression levels peaked approximately ten days post-infection (333). Having Vif
available in excess could lead to a situation where Vif is saturating and able to interact
with increasing amounts of Apobec3G. If that were the case , the NL4.3/KKRK Vif
would then eventually overcome its inability to drive degradation of Apobec3G by
exploiting its ability to sequester Apobec3G in the nucleus. This would be equally as
effective since Apobec3G would no longer be in the cytoplasm for virion packaging. It is
known that the NL4.3/KKRK virus that eventually grows out does not contain rever;ions
at the KKRK motif or compensatory mutations in Vif. Therefore, it is clear that the
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kinetics of Apobec3G and Vif expression must also be considered when investigating Vif
function.
D. Vif can utilize a second pathway for Apobec3G neutralization
One recent study suggested that Vif may be able to form aggresome like
structures under certain physiological conditions (352). However, the authors of this
study felt that this was a non-specific event. At the same time, additional publications
indicated the potential for a second pathway for Vif function (334, 335 , 338). Based on
the observations made while examining subcellular localization of Vif in Chapter IV , it
was proposed that aggresome formation was specific and could serve as a potential
second pathway for Vif function.
The data presented in Chapter V shows that Vif forms aggresomes, recruits
Apobec3G into aggresomes , and that aggresome formation is functionally important for
production of infectious virions. Some of these observations are in agreement with those
presented by Wichroski et al. and a previous study by Karczewski et al. The Karczewski
study was the first to show perinuclear aggregates of Vif surrounded by vimentin (351).
However, this work was published prior to the identification of Apobec3G and the
authors were unable to assign any relevance to these structures. The Wichroski
publication confirmed the presence of Vif perinuclear aggregates and suggested that they
were indeed aggresomes (352). While this study did show that Apobec3G also
colocalized to these aggresome structures , they provided no conclusive evidence that the
structures were aggresomes and suggested that they were non-specifically formed. Here
it is shown that the observed Vif-Apobec3G perinuclear aggregates contain the
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aggresome marker ubiquitin and that Vif can associate with the additional aggresome
markers Hsp70 and vimentin. Importantly, the Vif aggregates are shown to contain the
aggresome regulating protein HDAC6 and in vitro assays demonstrate that Vif and
HDAC6 bind. Additionally, fonnation of these aggresomes is dependent on an intact
microtubule network, also a hallmark of cellular aggresomes. This conclusively shows
that the perinuclear aggregates of Vif and Apobec3G are aggresomes.
While the presence of aggresome markers confirms that the perinculear
aggregates are cellular aggresomes , the question of functional relevance of these
structures remained. It is clear that a second pathway for Apobec3G neutralization must
exist since even when Vif is present and capable of degrading Apobec3G via the
proteasome, a significant amount, up to 26% , of Apobec3G is stil detected in the cell
(329 330). The studies presented in Chapter IV highlight the importance of complete
neutralization of Apobec3G to allow for production of infectious virions, leaving a pool
of free, cytoplasmic Apobec3G disrupts viral replication. Also
, when the degradation
assays were performed in Chapter IV , NL4. 3/WT did drive degradation of Apobec3G at a
significantly higher level than NL4.3/KKRK, but the observed Apobec3G degradation
was not complete. This again indicates that a second pathway must function in
conjunction with the proteasome degradation of Apobec3G. Therefore
, a second
pathway, independent of proteasomal degradation
, must be available for Vif inhibition of
Apobec3G. The proposal of a second pathway for Apobec3G neutralization by direct
interaction with Vif provided support for the functional relevance of aggresome
formation (334 , 335 , 338). Vif interaction with Apobec3G in the cytoplasm may not be
sufficient to disrupt Apobec3G binding to NC if the two binding sites are separate
, as
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may be the case since Vif-Apobec3G binding appears to be direct (335) while NC-
Apobec3G binding may be mediated by an RNAbridge (313 , 3l5). Therefore , Vif
would need to not only bind Apobec3G, but also to sequester it at a site distant from the
virus assembly and budding area. Since the aggresomes are located in a perinuclear
region and are trapped within a vimentin cage , this would allow Vif to trap Apobec3G in
an area of the cell where it could not access NC. Disrupting aggresome formation by
inducing collapse of the microtubule network or by inhbiting the HDAC6 protein resulted
in production of less infectious virions from cells where Apobec3G was expressed.
These treatments did not inhibit virus produced from cells where Apobec3G was not
expressed.
One interesting observation here i that proteasome inhibition resulted in
decreased infectivity for viruses produced from both non-permissive and permissive cell
lines. This could be attributed to a suboptimal dose of proteasome inhibitor, or it could
be due to the levels of Apobec3G present. Most previous experiments done with
proteasome inhibitors used cells that were cotransfected with Vif and Apobec3G or used
cells that were stably transfected with Apobec3G and typically Vif was in excess in those
studies (328-332 , 361) Here , cell lines that endogenously express Apobec3G were used,
allowing for a more relevant evaluation of the system. The results of these experiments
indicate that aggresome formation could be the second pathway for Apobec3G inhibition.
This would serve as a parallel pathway for preventing Apobec3G incorporation into the
vlfon.
The ability of Vif to inhibit Apobec3G by aggresome formation is not unique as it
has previously been reported that the adenovirus E1B protein inhibits cellular p53 by
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sequestering p53 into an aggresome like cytoplasmic structure (398). Vif may have
evolved two distinct mechanisms for acce sing separate pools of Apobec3G present in
the cell. The ability to use two pathways may be modulated by phosphorylation of Vif as
proposed by Mehle et al (338). The need for proteasomal degradation of Apobec3G has
been clearly established. Here, a second pathway for Apobec3G inhibition by
sequestration into an aggresome structure has been demonstrated. This leads to the
proposal of a model whereby Vif can exploit two pathways for Apobec3G neutralization
either directed degradation via assembly with a EloBC-Cul5-E3 ubiquitin ligase complex
or via interaction with HDAC6 and formation of an aggresome as a storage unit.
E. Conclusions
In conclusion, the subcellular localization of HIV- 1 Vif is critical for Vif function.
By mislocalizing Vif to the nucleus during the viral life cycle, it is unable to prevent
virion incorporation of Apobec3G. Viruses that package Apobec3G are significantly less
infectious due to the ability of the Apobec3G cytidine deaminase to disrupt the reverse
transcription process in target cells. This conclusively shows that the cytoplasmic
localization of Vif is imperative for proper Vif function.
Also, a second pathway for Vif function has been defined. This pathway involves
the interaction of Vif with HDAC6 to form an aggresome. Vif can recruite Apobec3G
into the aggresome and neutralize Apobec3G by sequestration. The aggresome
assembles in the periphery and is transported along the microtubule network until it
reaches the centrosome. It is then surrounded by a vimentin cage and serves as a long-
term storage compartment until the proteasome can degrade the proteins.
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